Organization
Dana-Farber Cancer Institute
204 clinical trials
405 abstracts
33 posters
Abstract
INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.Org: Memorial Sloan Kettering Cancer Center, Erasmus MC Cancer Institute, Tel-Aviv Sourasky Medical Center/Tel-Aviv University, Pitié Salpêtrière Hospital, Duke University Medical Center,
Abstract
PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).Org: Memorial Sloan Kettering Cancer Center, Alliance Statistics and Data Center, Mayo Clinic, Department of Radiology, Department of Colorectal Oncology,
Abstract
Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC).Org: Dana-Farber Cancer Institute, Medical Faculty Mannheim, Pangaea Oncology, Queen Mary University of London, Centre Léon Bérard,
Abstract
Association of tumor-infiltrating lymphocytes (TILs) with clinicopathologic characteristics and prognosis in young women with HR+/HER2- breast cancer (BC).Org: Dana-Farber Cancer Institute, Weill Cornell Medicine, Stanford Comprehensive Cancer Institute, University of Colorado Cancer Center, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV,
Abstract
Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): The impact of repeat biopsies.Org: Massachusetts General Hospital, Massachusetts General Hospital Cancer Center, Dana-Farber Cancer Institute, Harvard Medical School,
Abstract
Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials.Org: University of Oxford, Centre for Public Health, Karolinska Institutet, Fred Hutchinson Cancer Research Center, Peter MacCallum Cancer Centre, Melbourne, Australia,
Abstract
Evaluation of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores in premenopausal women with early-stage HR+ breast cancer: A secondary analysis of the SOFT trial.Org: University of Chicago, European Institute of Oncology, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Peter MacCallum Cancer Centre, Melbourne, Australia, International Breast Cancer Study Group,
Abstract
Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials.Org: NSABP, Dana-Farber Cancer Institute, University of Michigan Health System Comprehensive Cancer Center, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, The Institute of Cancer Research,
Abstract
Phase II trial of pembrolizumab in patients with brain metastases.Org: Massachusetts General Hospital and Harvard Medical School, Dana-Farber Cancer Institute, Dana-Farber/Brigham and Women's Cancer Center, Massachusetts General Hospital, Yale University,
Abstract
Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).Org: Memorial Sloan Kettering Cancer Center, Kyushu University, University Hospital Essen, P.A. Herzen Moscow Oncological Research Institute, University of Miami Sylvester Comprehensive Cancer Center,
Abstract
Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.Org: Dana-Farber Cancer Institute, Gustave Roussy Cancer Center, Clinical Hospital No. 1 of the Poznan University of Medical Sciences, Memorial Sloan Kettering Cancer Center, Hospital Universitario 12 de Octubre,
Abstract
Prognostic impact of PSA nadir (n) ≥0.1 ng/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative.Org: Dana-Farber Cancer Institute, St. Luke’s Hospital, Division of Urology, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Tor Vergata University of Rome,
Abstract
Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma.Org: Dana-Farber Cancer Institute, UPMC Hillman Cancer Center, Cleveland Clinic Lerner College of Medicine, Princess Margaret Cancer Centre, Moffitt Cancer Center,
Abstract
Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL): Top line results of the pivotal FELIX study.Org: University College London Cancer Institute, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, Manchester Royal Infirmary, Texas Transplant Physician Grp, PLLC,
Abstract
Epcoritamab + R2 regimen and responses in high-risk follicular lymphoma, regardless of POD24 status.Org: Dana-Farber Cancer Institute, Institut Català D'Oncologia, Leiden University Medical Center, Rigshospitalet, Copenhagen University Hospital, Ronald Reagan University of California Los Angeles Medical Center,
Abstract
Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance).Org: Alliance Statistics and Data Management Center, Alliance Protocol Operations Office, Illinois CancerCare, Mayo Clinic, Trinity Health Saint Joseph Mercy Hospital,
Abstract
Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM).Org: University of Chicago, Novartis Institutes for BioMedical Research, Medical College of Wisconsin, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center,
Abstract
Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC.Org: Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Memorial Sloan Kettering Cancer Center, Vall d’Hebron University Hospital/VHIO, Lausanne University Hospital, William Osler Health System,
Abstract
Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.Org: University of Texas MD Anderson Cancer Center, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, University Duisburg-Essen, German Cancer Consortium, Instituto Oncológico Fundación Arturo López Pérez,
Abstract
Randomized phase II trial of dabrafenib and trametinib with or without navitoclax in patients (pts) with BRAF-mutant (MT) metastatic melanoma (MM) (CTEP P9466).Org: New York University School of Medicine, The Ohio State University Comprehensive Cancer Center, Duke University Medical Center, Northwestern University, University of Colorado Comprehensive Cancer Center,
Abstract
Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.Org: Laura and Isaac Perlmutter Cancer Center, Sir Charles Gairdner Hospital, Washington University Oncology, Sarah Cannon Research Institute/Tennessee Oncology, One Clinical Research and Edith Cowan University,
Abstract
Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.Org: Children’s Hospital of Philadelphia, University of Pennsylvania, Children's Oncology Group Statistics and Data Center, University of Florida, CanSino Biologics, Dana Farber Cancer Institute, Boston, MA,
Abstract
Feasibility of the Poverty-Targeted Pediatric Cancer Resource Equity (PediCARE) intervention.Org: Children's Hospital of Philadelphia, DFCI/PCC Fellowship Program - Attendings, Dana-Farber Cancer Institute, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, University of Alabama at Birmingham,
Abstract
Second primary breast cancer in young breast cancer survivors.Org: Harvard School of Public Health, Beth Israel Deaconess Medical Center and Harvard Medical School, Stanford Comprehensive Cancer Institute, Odette Cancer Centre, Beth Israel Deaconess Medical Center,
Abstract
Polygenic risk score calibration and association with breast cancer in diverse ancestries.Org: Myriad Genetics, Inc., Vanderbilt University Medical Center, Abramson Cancer Center, University of Pennsylvania, Providence Health/St John Cancer Institute, Memorial Sloan Kettering Cancer Center,
Abstract
A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).Org: Duke University Medical Center, Mayo Clinic, Vanderbilt University Medical Center, Virginia Commonwealth University Health System, Duke Cancer Institute,
Abstract
Efficacy of combination lurbinectedin (LURBI) + doxorubicin (DOX) from the phase 1B soft-tissue sarcoma (STS) lead-in to a randomized phase 2 trial in leiomyosarcoma (LMS).Org: MGH Cancer Center, Massachusetts General Hospital, Mayo Clinic, Ludwig Center at Harvard Medical School, Dana-Farber Cancer Institute,
Abstract
Effect of a telephone-based weight loss intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.Org: Weill Cornell Medicine, Mount Sinai Hospital-Breast Medical Oncology, Massachusetts General Hospital, UM/Sylvester Comprehensive Cancer Center, UNC Patient Advocates for Research Council,
Abstract
Reduced symptom burden after implementation of an electronic symptom management program.Org: MaineHealth Cancer Care, Department of Medical Oncology, Dana-Farber Cancer Institute, Dartmouth-Hitchcock Medical Center, WVU Cancer Institute, Memorial Sloan Kettering Cancer Center,
Abstract
Association of tumor infiltrating lymphocyte quantity with survival in patients (pts) with metastatic breast cancer (MBC) receiving microtubule-targeting agents: Post hoc analysis CALGB 40502 (Alliance).Org: Columbus, OH, GZA-ZNA Hospitals, Joan and Sanford I Weill Medical College of Cornell University, Weill Cornell Medicine, New York, NY,
Abstract
BRACELET-1 (PrE0113): Inducing an inflammatory phenotype in metastatic HR+/HER2- breast cancer with the oncolytic reovirus pelareorep in combination with paclitaxel and avelumab.Org: ECOG-ACRIN Biostatistics Center, University Hospitals Seidman Cancer Center, University of Miami Sylvester Cancer Center, Ohio State University Comprehensive Cancer Center, Temple University Health System,
Abstract
A genomic score to predict local control among patients with brain metastases managed with radiation.Org: Brigham and Women's Hospital, Mater Private Hospital, Dana-Farber Cancer Institute, Broad Institute of Harvard and MIT, Boston, MA,
Abstract
Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR-mutated non-small cell lung cancer.Org: University of California, San Francisco, The University of California, San Francisco, University of Colorado Comprehensive Cancer Center, UC Davis Comprehensive Cancer Center, Dana-Farber Cancer Institute,
Abstract
Primary overall survival analysis of the phase 3 randomized ZUMA‑7 study of axicabtagene ciloleucel versus standard‑of‑care therapy in relapsed/refractory large B-cell lymphoma.Org: Vanderbilt University Cancer Center, University of Amsterdam, Stanford University School of Medicine, Washington University School of Medicine, Hematology Department, Institut Català d'Oncologia-Hospitalet,
Abstract
Clinico-molecular characteristics associated with outcomes in breast cancer patients treated with CDK4/6 inhibitors: Results from the AURORA Molecular Screening Initiative.Org: Université Libre de Bruxelles (ULB), Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium, Breast International Group, Brussels, Belgium, Dana-Farber Cancer Institute, Vall d’Hebron Institute of Oncology (VHIO),
Abstract
Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study.Org: Harvard Medical School, Massachusetts General Hospital Cancer Center, Dana-Farber Cancer Institute, Boston, MA,
Clinical trial
A Randomized Phase II Trial of Carboplatin With or Without Nivolumab in First-line Metastatic Triple-negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2021-09-28
Abstract
Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Johns Hopkins University, Baltimore, MD,
Abstract
Enfortumab vedotin (EV) in triple-negative breast cancer (TNBC) and HR+/HER2- breast cancer (BC) cohorts of EV-202.Org: Dana-Farber Cancer Institute, University of Wisconsin, University of California Irvine, University of Colorado Denver Department of Radiation Oncology, Perlmutter Cancer Center, NYU Langone Health,
Abstract
Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).Org: Winship Cancer Institute, Emory University, Atlanta, GA, USA, Cancer Research and Biostatistics, University of Kansas Medical Center, ASCO,
Abstract
Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.Org: Winship Cancer Institute of Emory University, IRCCS Ospedale San Raffaele, Sarah Cannon Research Institute/Tennessee Oncology, Lifespan Cancer Institute, Legorreta Cancer Center at Brown University,
Abstract
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.Org: Dana-Farber Cancer Institute, University of Chicago Medicine, UNC Lineberger Comprehensive Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Emory University Hospital,
Abstract
ECOG-ACRIN EAZ171: Prospective validation trial of germline variants and taxane type in association with taxane-induced peripheral neuropathy (TIPN) in Black women with early-stage breast cancer.Org: Indiana University Simon Comprehensive Cancer Center, Indianapolis, IN, Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Malden, MA,
Abstract
Efficacy of eSyM: Acute care utilization among patients with cancer who do versus do not report ePROs.Org: Dana-Farber Cancer Institute, MaineHealth Cancer Care, Lifespan Cancer Institute, WVU Cancer Institute, Baptist Cancer Center,
Abstract
Associations of social determinants of health with avoidance of information, treatment receipt, and physician mistrust for women with breast cancer.Org: Dana-Farber Brigham Cancer Center, Dana-Farber Cancer Institute, Boston Medical Center, Boston University, Survey and Data Management Core,
Abstract
Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma.Org: Berry Consultants, LLC, Global Coalition for Adaptive Research, Hunstman Cancer Institute at the University of Utah, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA,
Abstract
A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL).Org: Dana-Farber Cancer Institute, DFCI/PCC Fellowship Program - Attendings, Massachusetts General Hospital, Kite Pharma, Division of Neuroradiology,
Abstract
First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations.Org: KSQ Therapeutics, Cambridge, MA, Roche Pharma Research and Early Development, Roche Innovation Center, Dana-Farber Cancer Institute, Hackensack University Medical Center,
Abstract
A phase II/III study of peri-operative nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of the neoadjuvant pathologic complete response (pCR) rate (ECOG-ACRIN EA2174).Org: University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA, Dana-Farber Cancer Institute, Boston, MA,
Abstract
A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186.Org: Fox Chase Cancer Center, Dana-Farber Cancer Institute, Wake Forest University Department of General Internal Medicine, Stanford University School of Medicine, ThedaCare Regional Medical Center,
Abstract
Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.Org: Memorial Sloan Kettering Cancer Center, University of Bari "A. Moro" and Policlinico Consorziale, Kyushu University, Texas Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea,
Abstract
Partitioned overall survival: Comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma (aRCC).Org: Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Georgetown-Lombardi Comprehensive Cancer Center, Bristol Myers Squibb, Dana-Farber Cancer Institute and International Breast Cancer Study Group Statistical Center,
Abstract
Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.Org: Euromed service, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, The University of Texas MD Anderson Cancer Center, British Columbia Cancer Agency, Asan Medical Center,
Abstract
Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial.Org: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Dana-Farber Cancer Institute, Harvard Medical School, Barts Cancer Institute,
Abstract
A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance).Org: Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Duke University Medical Center, Duke University Department of Biostatistics and Bioinformatics,
Abstract
Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore.Org: Memorial Sloan Kettering Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, Institut Gustave Roussy, University Hospital Essen,
Abstract
Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153).Org: University of Wisconsin Carbone Cancer Center, Madison, WI, Dana-Farber Cancer Institute, Boston, MA, University of Wisconsin,
Abstract
Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas.Org: Lifespan Cancer Institute, Rhode Island Hospital, Providence, RI, Women and Infants Hospital of Rhode Island, University of Illinois at Chicago,
Abstract
Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation.Org: City of Hope National Medical Center, CIBMTR (Center for International Blood and Marrow Transplant Research), NMDP, Medical College of Wisconsin, Memorial Sloan Kettering Cancer Center,
Abstract
Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib/II study.Org: Autolus Therapeutics, H. Lee Moffitt Cancer Center and Research Institute, The David and Etta Jonas Center for Cellular Therapy, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute,
Abstract
Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma.Org: Mayo Clinic, Memorial Sloan Kettering Cancer Center, Cleveland Clinic Lerner College of Medicine, The Ohio State University - Division of Hematology, Washington University School of Medicine,
Abstract
Efficacy and safety of erdafitinib in pediatric patients with advanced solid tumors and FGFR alterations in the phase 2 RAGNAR trial.Org: Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg University Hospital and German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT), Memorial Sloan Kettering Cancer Center, FLENI,
Abstract
Impact of an objective scoring system on initiation of therapy in patients with International Neuroblastoma Risk Group Staging System (INRGSS) stage MS neuroblastoma: A report from the Children’s Oncology Group.Org: Children's Hospital Colorado, Aurora, CO, Children's Oncology Group Statistics and Data Center, University of Florida, Baylor College of Medicine, Children's Hospital of Philadelphia, Roswell Park Cancer Institute Department of Cancer Prevention and Population Sciences,
Abstract
A pilot study of post-consolidation chemoimmunotherapy for high-risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group.Org: University of Chicago Medical Center, Chicago, IL, Children's Oncology Group Statistics and Data Center, University of Florida, University of Florida-Health Cancer Center, Orlando Health, Orlando, FL, Children's Oncology Group Statistics & Data Center, Department of Biostatistics & Data Science,
Abstract
Evolution of tisagenlecleucel use for the treatment of pediatric and young adult relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL): Center for International Blood & Marrow Transplant Research (CIBMTR) registry results.Org: Dana-Farber Cancer Institute, Boston Children's Hospital Cancer and Blood Disorders Center, Memorial Sloan Kettering Cancer Center, University of Colorado Denver, Children's Mercy Hospital,
Abstract
Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial.Org: Memorial Sloan Kettering Cancer Center, Chris O'Brien Lifehouse, Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Medical Oncology and Sarcoma Center, Dana-Farber Cancer Institute,
Abstract
SU2C-SARC032: A randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma.Org: UPMC Hillman Cancer Center, Mayo Clinic Rochester, Melanoma Institute Australia, University of Sydney and Sydney Cancer Centre, Chris O'Brien Lifehouse,
Abstract
SARC037: Phase II results of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in patients (pts) with relapsed/refractory Ewing sarcoma (ES).Org: Children's Hospital of Philadelphia, Mayo Clinic, Department of Population Health Sciences, Weill Cornell Medicine, Children’s Hospital Los Angeles,
Abstract
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A).Org: AstraZeneca, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Dana-Farber Cancer Institute,
Abstract
International medical graduates (IMG) representation at international oncology conference meetings.Org: Roswell Park Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Gazi University Faculty of Medicine, University of Arkansas for Medical Sciences,
Abstract
Going back home: Understanding the challenges of international medical graduates (IMGs) in oncology.Org: University of Miami Sylvester Comprehensive Cancer Center, Capital Health, University of California, San Francisco, NYU Langone Health, Mayo Clinic,
Abstract
Real-world and clinical trial validation of a deep learning radiomic biomarker for PD-(L)1 immune checkpoint inhibitor response in stage IV NSCLC.Org: Onc.AI, Pfizer Inc., Department of Radiation Oncology and Radiology, Dana-Farber Cancer Institute, Brigham and Women’s Hospital,
Abstract
Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC041: A phase II study of alisertib in endocrine resistant metastatic breast cancer (MBC).Org: Mayo Clinic, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, University of Michigan, Duke University Medical Center/Duke Cancer Institute,
Abstract
Comparison of expert treatment recommendations versus community healthcare providers: Analysis from an online decision support tool for metastatic breast cancer.Org: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Sarah Cannon Research Institute/Tennessee Oncology, Emory University at Winship Cancer Institute, Clinical Care Options, LLC,
Abstract
BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2− breast cancer (BC).Org: Henri and Belinda Termeer Center for Targeted Therapies, Massachusetts General Hospital, Boston, MA, USA, Massachusetts General Hospital, Florida Cancer Specialists/Sarah Cannon Research Institute, University of Virginia, Charlottesville, VA, USA, Memorial Sloan Kettering Cancer Center,
Abstract
Comprehensive analysis of TROP2, PD-L1, stromal (s)TILs, and HER2 expression patterns in patients (pts) with metastatic HR+HER2- breast cancer.Org: Dana-Farber Cancer Institute, University of Milan and European Institute of Oncology, IRCCS, Brigham and Women's Hospital, University of Milano, European Institute of Oncology, Division of Early Drug Development, European Institute of Oncology,
Abstract
Novel epigenomic liquid biopsy assay to predict estrogen receptor (ER) status and to infer ER pathway activation in breast cancer.Org: Dana-Farber Cancer Institute, Precede Biosciences, Harvard Medical School,
Abstract
Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study.Org: Baylor University Medical Center, Texas Oncology, The US Oncology Network, International Breast Cancer Center (IBCC), Quironsalud Group,
Abstract
Genomic alterations in DNA damage response (DDR) genes in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG): Biomarker results from TROPICS-02 study.Org: David Geffen School of Medicine at UCLA, University of California Irvine, Jonsson Comprehensive Cancer Center, Los Angeles, CA, Gilead Sciences, Inc.,
Abstract
Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer.Org: Dana-Farber Cancer Institute, Yale School of Medicine, University of Pittsburgh Medical Center (UPMC), Yale Cancer Center, Harvard Medical School,
Abstract
Sequential combination of sacituzumab govitecan and talazoparib in metastatic triple negative breast cancer (mTNBC): Results from a phase II study.Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Dana-Farber Cancer Institute, UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA,
Abstract
Analysis of the sensitivity to endocrine therapy (SET) assay in the PALLAS adjuvant trial of palbociclib in HR+/HER2- breast cancer (ABCSG-42/AFT-05/BIG-14-13).Org: Dana-Farber Cancer Institute, Mayo Clinic, Medical University of Vienna, Washington University School of Medicine, The University of Texas MD Anderson Cancer Center,
Abstract
Correlation of TILs indices generated by visual review and digital computational algorithm with outcomes from preoperative chemotherapy for TNBC in TBCRC 030.Org: Dana-Farber Cancer Institute, 4D Path Inc., Vanderbilt University Medical Center, University of Pittsburgh, O'Neal Comprehensive Cancer Center at UAB,
Abstract
The landscape of the intestinal microbiome amongst patients with newly diagnosed invasive breast cancer (BC) and ductal carcinoma in situ (DCIS).Org: Dana-Farber Cancer Institute, Department of Biostatistics & Data Science, Microbiome Analysis Core, Harvard T.H. Chan School of Public Health, Harvard Medical School,
Abstract
The immunomodulatory impacts of endocrine therapy on host immunity in early-stage hormone receptor positive, HER2 negative breast cancer.Org: Dana-Farber Cancer Institute, Duke Cancer Institute, Duke University Medical Center, The University of North Carolina at Chapel Hill, UT Southwestern Medical Center,
Abstract
Prevalence and dynamics of circulating tumor DNA (ctDNA) among patients (pts) with HER2+ breast cancer (BC) receiving neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) in the DAPHNe trial.Org: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, DFCI/PCC Fellowship Program - Attendings, Personalis, Inc.,
Abstract
Automated prediction of response to neoadjuvant chemotherapy from digitized H&E slides of pre-treatment core needle biopsies in germline BRCA carriers with HER2-negative breast cancer (TBCRC 031).Org: Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Dana-Farber Cancer Institute, 4D Path Inc.,
Abstract
Survival outcomes and treatment patterns by tumor subtype (TS) in stage III inflammatory and non-inflammatory breast cancer (BC).Org: Dana-Farber Cancer Institute/Harvard Medical School, Grupo Oncológico Cooperativo del Sur, Brigham and Women's Hospital, Tufts Medical Center/Tufts University, Michigan State University,
Abstract
ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd).Org: The University of Texas MD Anderson Cancer Center, US Oncology Research/Maryland Oncology Hematology, Norton Healthcare, New York Presbyterian, Northwest Medical Specialties,
Abstract
First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer.Org: Vall d’Hebron University Hospital/VHIO, Vall d'Hebron Institute of Oncology, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Instituto Valenciano de Oncología,
Abstract
International phase 3 clinical trial evaluating PF-07220060 plus fulvestrant in patients with HR+/HER2− advanced/metastatic breast cancer with progression after a prior CDK4/6 inhibitor.Org: Dana-Farber Cancer Institute, Institut Jules Bordet, Université Libre de Bruxelles, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Centro de Pesquisa Clínica Hospital São Lucas da PUCRS,
Abstract
pionERA Breast Cancer (BC): Phase III study of first-line (1L) giredestrant vs. fulvestrant, both combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), in patients (pts) with estrogen receptor-positive (ER+), HER2– locally advanced/metastatic BC (LA/mBC) with resistance to prior adjuvant (adj) endocrine therapy (ET).Org: Winship Cancer Institute of Emory University, Dana-Farber Cancer Institute, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, University Hospital Erlangen, Hospital Alemán,
Abstract
TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician’s choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769).Org: Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, Dana-Farber Cancer Institute, Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC,
Abstract
Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy: ECOG-ACRIN EA1211/DIRECT trial.Org: Cancer Research @UCC, Brown University - ECOG-ACRIN Biostatistics Center, Dana-Farber Cancer Institute, Saint Vincent Hospital Cancer Center Green Bay, University of Alabama at Birmingham Comprehensive Cancer Center,
Abstract
The oncology care model and initiation of systemic therapy for cancer.Org: Harvard Medical School, Brigham and Women's Hospital, Department of Health Care Policy, Dana-Farber Cancer Institute, Dartmouth Cancer Center, Lebanon, NH,
Abstract
Relationship between receipt of combined axillary dissection and nodal irradiation and age.Org: Brigham and Women's Hospital, Dana-Farber Cancer Institute, Yale University,
Abstract
Characterizing the authorship of phase 3 randomized clinical trials in oncology, 1960-2023.Org: Brown University/Legorreta Cancer Center, Dana-Farber Cancer Institute, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, University of Kansas Medical Center,
Abstract
Options for evaluating communication strategies in treatment and clinical trial discussions.Org: University of Wisconsin, Dana-Farber Cancer Institute, Madison, WI, Boston, MA,
Abstract
Post-acute care facility utilization and outcomes among Medicare beneficiaries undergoing inpatient cancer surgery.Org: Massachusetts General Hospital, Harvard Medical School, Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Dana-Farber Cancer Institute,
Abstract
Relationship between cognitive and emotional domains of prognostic awareness with quality of life and psychological distress in patients with advanced cancer.Org: The Warren Alpert Medical School of Brown University, University of Massachusetts Chan Medical School, Massachusetts General Hospital, Harvard Medical School, Brigham and Women’s Hospital,
Abstract
EROS: Engendering reproductive health within oncologic survivorship—ECOG-ACRIN E1Q11 paradoxical provision of reproductive health.Org: Cook County Hospital, Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Lewis Cancer & Research Pavilion at St. Joseph's Candler/GA NCORP, SHCC MU-NCORP,
Abstract
If you build it, they will come: Success of the EROS (Engendering Reproductive Health Within Oncologic Survivorship)—ECOG-ACRIN E1Q11 in recruitment of minority patients.Org: Cook County Hospital, Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, Lewis Cancer & Research Pavilion at St. Joseph's Candler/GA NCORP, SHCC MU-NCORP,
Abstract
Inequities in timely treatment (Tx) initiation for patients (pts) with acute myeloid leukemia (AML) treated in a predominantly community setting in the United States (US).Org: Genentech, The James Cancer Center, The Ohio State University Comprehensive Cancer Center, University of Chicago, AbbVie Inc.,
Abstract
Identifying eligibility criteria that perpetuate race/ethnic disparities in acute myeloid leukemia (AML) clinical trial participation.Org: Dana-Farber Cancer Institute, University of Chicago Medicine, University of Chicago Medical Center, Chicago, IL, University of Chicago, University of Illinois at Chicago,
Abstract
Potentially inappropriate medications and their association with frailty, unplanned hospitalizations, and mortality in patients with cancer treated in the national U.S. Veterans Affairs Healthcare System.Org: VA Boston Healthcare System, Brigham and Women's Hospital, VA Greater Los Angeles Healthcare System, Massachusetts Veterans Epidemiology Research and Information Center, Harvard Medical School,
Abstract
Multi-cancer early detection (MCED) test performance in cancer survivors.Org: Dana-Farber Cancer Institute, GRAIL, LLC, a subsidiary of Illumina, Inc.,
Abstract
GUIAR: Promoting lung cancer screening in Hispanic head and neck cancer survivors.Org: University of Miami Sylvester Comprehensive Cancer Center, Dana-Farber Cancer Institute, University of Miami Health System,
Abstract
Barriers to accrual and enrollment in brain tumor trials.Org: Dana-Farber Cancer Institute, Massachusetts General Hospital, University of California Irvine, The University of Texas MD Anderson Cancer Center, The University of Texas Health Science Center School of Nursing,
Abstract
A phase II, open label, single arm study of nivolumab for recurrent or progressive IDH mutant gliomas with prior exposure to alkylating agents.Org: Columbia University Irving Medical Center, New York, NY, USA, Dana-Farber Cancer Institute, Miami Cancer Institute, Baptist Health South Florida, Rhode Island Hospital,
Abstract
Deciphering pediatric low-grade glioma trajectories: Deep learning–based volumetrics for patients under surveillance.Org: Brigham and Women's Hospital, Division of Neuroradiology, Perelman School of Medicine, University of Pennsylvania, Department of Radiology,
Abstract
A randomized, controlled, phase 2 trial of nivolumab plus standard-dose or low-dose bevacizumab for recurrent glioblastoma (NAVAL).Org: Miami Cancer Institute, Baptist Health South Florida, Cleveland Clinic Lerner College of Medicine, Department of Internal Medicine, William Beaumont University Hospital, The University of North Carolina at Chapel Hill,
Clinical trial
Phase II Study Of Combination Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast CancerStatus: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
A Phase 1b Study of Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cell Therapy in Combination With N-803 (Il-15 Superagonist) in Recurrent Ovarian CancerStatus: Not yet recruiting, Estimated PCD: 2026-11-30
Clinical trial
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCTStatus: Active (not recruiting), Estimated PCD: 2024-05-24
Clinical trial
Phase 2 Proof-of-Concept Trial Testing the PARP Inhibitor Niraparib in Patients With Pancreatic Cancer Harboring Deficiencies in Homologous Recombination DNA RepairStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Clinical trial
'ADVANCE' (A Pilot Trial) ADjuVANt Chemotherapy in the Elderly: Developing and Evaluating Lower-Toxicity Chemotherapy Options for Older Patients With Breast CancerStatus: Active (not recruiting), Estimated PCD: 2020-11-10
Clinical trial
A Phase II Study of Rituximab/Bendamustine Followed by Rituximab/Cytarabine for Untreated Mantle Cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2015-02-01
Clinical trial
Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung CancerStatus: Active (not recruiting), Estimated PCD: 2023-02-28
Clinical trial
A Phase II Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase I Trial of a Dendritic Cell Activating Scaffold Incorporating Autologous Melanoma Cell Lysate (WDVAX) in Metastatic Melanoma PatientsStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
SAVE (Safe Accelerated Venetoclax Escalation): A Phase Ib Study of Venetoclax Monotherapy With Accelerated Dose Ramp-up in Patients With CLLStatus: Recruiting, Estimated PCD: 2025-06-02
Clinical trial
A Phase II Study With a Safety lead-in of Nivolumab in Combination With Bevacizumab or in Combination With Bevacizumab and Rucaparib for the Treatment of Relapsed Epithelial Ovarian, Fallopian Tube or Peritoneal CancerStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Abstract
Impact of hormone receptor status and tumor subtypes on clinical behavior and outcomes of breast cancer in young BRCA carriers.Org: Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genoa, Genoa, Italy, Academic Trials Promoting Team, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Brussels, Belgium, U.O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genova, Italy, Department of Medical Oncology, Universite Paris Cité, Institut Curie, Paris, France, Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea,
Abstract
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study.Org: Institut Català D'Oncologia, IDIBELL, Seoul National University Hospital, Cancer Research Institute, Aichi Cancer Center Hospital,
Abstract
Shareable artificial intelligence to extract cancer outcomes from electronic health records.Org: Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Dana-Farber Cancer Institute, Boston, MA, USA, Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, Memorial Sloan Kettering Cancer Center, New York, NY, Dana-Farber Cancer Institute, Boston, MA, Dana-Farber Cancer Institute,
Abstract
Early results of the PASS-01 trial: Pancreatic adenocarcinoma signature stratification for treatment-01.Org: Department of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada, Department of Medical Oncology, The Sidney Kimmel Cancer Center at Johns Hopkins, Cancer Convergence Institute, Bloomberg-Kimmel Institute, Baltimore, MD, Ontario Institute for Cancer Research, Toronto, ON, Canada, Northwell Health Cancer Institute, Lake Success, NY, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD,
Abstract
Health-related quality of life (HRQOL) results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer.Org: University of Kansas Medical Center, Mayo Clinic, Mayo Clinic Cancer Center, Washington University in St. Louis, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute,
Abstract
Safety and efficacy of first-in-class CXCR1/2 inhibitor SX-682 in combination with pembrolizumab (pem) in patients (pts) with metastatic melanoma (mMEL) with disease progression on anti–PD-1 therapy.Org: Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Mayo Clinic, Rochester, MN, USA, University of Rochester, Rochester, NY, Massachusetts General Hospital, Marblehead, MA, Dana-Farber Cancer Institute, Boston, MA, USA,
Abstract
Clinical behavior of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing: Results from an international cohort study.Org: IRCCS Ospedale Policlinico San Martino-University of Genova, Genoa, Italy, IRCCS Ospedale Policlinico San Martino, Genova, Italy, AOU Policlinico Paolo Giaccone, University of Palermo, Palermo, Italy, Institut Jules Bordet and Université Libre de Bruxelles (U.L.B), Brussels, Belgium, Department of Medical Oncology, Universite Paris Cité, Institut Curie, Paris, France,
Abstract
StrateGIST 1: A first-in-human (FIH), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors (TKIs).Org: University Hospitals Leuven, Department of General Medical Oncology, Leuven Cancer Institute, Leuven, Belgium, Oregon Health & Science University, Portland, OR, University of Miami – Sylvester Comprehensive Cancer Center, Miami, FL, Medical Oncology Department, Hospital Universitario Vall d'Hebron, Vall d'Hebron Institute of Oncology, Barcelona, Spain, Universitaetsklinikum Essen - Westdeutsches Tumorzentrum (WTZ) (West German Cancer Center), Essen, Germany,
Abstract
INAVO122: A phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients (pts) with PIK3CA-mutated, HER2-positive advanced breast cancer (HER2+ aBC).Org: Genentech, Product Development Data Science, F. Hoffmann-La Roche Ltd., F. Hoffmann-La Roche Ltd, Roche Products Ltd., Product Development Oncology, F. Hoffmann-La Roche Ltd.,
Abstract
Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation.Org: Pangaea Oncology, Breast Oncology Institute, Sermonix Pharmaceuticals, Mayo Clinic, Medical Oncology,
Clinical trial
Phase 1 Study of SL-401 in Combination With Azacitidine and Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Treatment-Naive Subjects With AML Not Eligible for Standard Induction and in Subjects With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or SL-401 in Combination With Azacitidine in Subjects With High-Risk Myelodysplastic Syndrome (MDS)Status: Recruiting, Estimated PCD: 2025-05-31
Clinical trial
Improving Quality of Life of Prostate Cancer Survivors With Androgen DeficiencyStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural MesotheliomaStatus: , Estimated PCD: 2019-06-07
Clinical trial
A Phase Ib Study of ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed Chronic Lymphocytic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2026-04-01
Clinical trial
Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in Squamous Cell Carcinoma of the Head and Neck (SCCHN)Status: Active (not recruiting), Estimated PCD: 2022-11-01
Clinical trial
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)Status: Active (not recruiting), Estimated PCD: 2019-08-26
Clinical trial
Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor PD-0325901 for Patients With KRAS Mutant Non-Small Cell Lung Cancer and Other Solid TumorsStatus: Completed, Estimated PCD: 2017-11-01
Clinical trial
Assessing the Impact of Scalp Cooling in With Metastatic Breast CancerStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML.Status: Active (not recruiting), Estimated PCD: 2018-02-01
Clinical trial
The Impact of HER2 Heterogeneity on the Treatment of Early-stage HER2-positive Breast Cancer: a Phase II Study of T-DM1 in Combination With Pertuzumab in the Preoperative SettingStatus: Active (not recruiting), Estimated PCD: 2018-06-01
Clinical trial
A Phase II Study of Ibrutinib in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma or Patients With Richter's SyndromeStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid CancerStatus: Completed, Estimated PCD: 2022-04-28
Abstract
Longitudinal stereotactic injections of oncolytic immunoactivating rQNestin34.5v.2 (CAN-3110) with concomitant biopsies for “-omic” analyses in recurrent glioblastoma (GBM).Org: Center for Neuro-Oncology, Dana-Farber Cancer Institute,
Abstract
A phase 1/2 study of BDC-3042, a novel dectin-2 agonistic antibody, in patients with advanced cancers.Org: Next Oncology Virginia and Virginia Cancer Specialists, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Dana-Farber Cancer Institute, Stanford University School of Medicine,
Abstract
Targeting replication stress in pancreatic cancer: A phase II trial investigating azenosertib in combination with gemcitabine in second-line advanced pancreatic cancer.Org: Dana-Farber Cancer Institute, Boston, MA, Massachusetts General Hospital,
Abstract
ERBB2 mutations and association with molecular phenotype in urothelial carcinoma.Org: Dana-Farber Cancer Institute, Yale University School of Medicine, Yale School of Medicine, Yale Cancer Center, Yale University,
Abstract
A randomized phase III clinical trial of yoga for chemotherapy-induced peripheral neuropathy treatment (YCT).Org: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
EROS: Engendering reproductive health within oncologic survivorship—ECOG-ACRIN E1Q11 assessing discrepancy in clinician-patient importance of sexuality over 2 years post-cancer diagnosis.Org: John H. Stroger, Jr. Hospital of Cook County, Dana-Farber Cancer Institute, ECOG-ACRIN Biostatistics Center, University of Illinois Urbana-Champaign, Lewis Cancer & Research Pavilion at St. Joseph's Candler/GA NCORP,
Abstract
Personalized circulating tumor (ct)DNA for monitoring disease status in HPV-negative head and neck squamous cell carcinoma.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Dana-Farber Cancer Institute, DFCI/PCC Fellowship Program - Attendings,
Abstract
Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment naïve UC (DAD-IO).Org: Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, AdventHealth Cancer Institute, The Lank Center for Genitourinary Oncology,
Abstract
Whole exome correlates in metastatic hormone sensitive prostate cancer (mHSPC): Results from E3805 CHAARTED.Org: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, University College London Cancer Institute, South Australian Immunogenomics Cancer Institute, University of Adelaide,
Abstract
A phase 1 trial evaluating the safety, tolerability, PK, and preliminary efficacy of QTX3034, an oral G12D-preferring multi-KRAS inhibitor, in patients with solid tumors with KRASG12D mutation.Org: Sarah Cannon Research Institute/Tennessee Oncology, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Duke University Medical Center, Huntsman Cancer Institute, University of Utah,
Abstract
The toxicity swimmer plot: A novel approach for evaluating patient-level toxicity following immune checkpoint inhibitor (ICI) therapy on the Checkmate 214 trial.Org: Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Georgetown-Lombardi Comprehensive Cancer Center, Dana-Farber Cancer Institute and International Breast Cancer Study Group Statistical Center,
Abstract
Phase II trial of regorafenib in metastatic medullary thyroid carcinoma (MTC) and radioactive iodine refractory differentiated thyroid carcinoma (RAIR DTC).Org: Dana-Farber Cancer Institute, Dana-Farber Cancer Institute and International Breast Cancer Study Group Statistical Center, Yale Cancer Center, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center,
Abstract
Prognostic impact of residual cancer burden (RCB) on long-term outcomes after neoadjuvant (neo) androgen receptor pathway inhibitor (ARPI) and radical prostatectomy (RP) for high-risk localized prostate cancer (HRLPC): A pooled analysis of phase 2 trials.Org: Dana-Farber Cancer Institute, Indiana University – Purdue University Indianapolis, Department of Data Sciences, Beth Israel Deaconess Medical Center, University of California Irvine,
Abstract
Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results.Org: Berry Consultants, LLC, Seagen, Cleveland Clinic Taussig Cancer Instititute, Yale School of Medicine, University of California Irvine,
Abstract
Association of CD8 T cell infiltration in the tumor microenvironment with survival outcomes in patients with metastatic renal cell carcinoma (mRCC).Org: Winship Cancer Institute of Emory University, Dana-Farber Cancer Institute,
Abstract
Molecular landscape and site of metastasis in PDAC.Org: The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Caris Life Sciences, Irving, TX, Dana-Farber Cancer Institute, Sidney Kimmel Medical College of Thomas Jefferson University, Thomas Jefferson University,
Abstract
Evaluating CR as a surrogate endpoint for PFS in R/R chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): A meta-analysis of randomized controlled trials (RCT).Org: Bristol Myers Squibb, EVERSANA, Burlington, ON, Canada, Oxford University Hospitals NHS Trust, Dana-Farber Cancer Institute,
Abstract
Assessing the environmental and downstream human health impacts of decentralizing cancer care.Org: Dana-Farber Cancer Institute, Massachusetts General Hospital,
Abstract
Genomic evolution of patients with myeloid neoplasms and known antecedent clonal hematopoiesis.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Leukemia, H. Lee Moffitt Cancer Center and Research Institute, Dana-Farber Cancer Institute,
Abstract
Serial circulating tumor DNA (ctDNA) sequencing to monitor response and define acquired resistance to letrozole/abemaciclib in endometrial cancer (EC).Org: Dana-Farber Cancer Institute, Guardant Health Inc., Brigham and Women's Hospital/Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Massachusetts General Hospital,
Abstract
Expression of the receptor tyrosine kinase AXL and clinical outcomes to cabozantinib and everolimus in patients with metastatic renal cell carcinoma enrolled in the METEOR trial.Org: Brigham and Women's Hospital/Massachusetts General Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, DFCI/PCC Fellowship Program - Attendings, Yale Cancer Center,
Abstract
STELLAR-305: A randomized phase 2/3 study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma.Org: Winship Cancer Institute, Emory University, Atlanta, GA, USA, The Institute of Cancer Research/The Royal Marsden Hospital, Fondazione IRCCS Istituto Nazionale Tumori and University of Milan, Cliniques Universitaires Saint-Luc,
Abstract
Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial.Org: University of Michigan Rogel Cancer Center, University of Chicago, Dana-Farber Cancer Institute, University of Wisconsin, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
Practice patterns in prostate cancer therapy among healthcare professionals: Comparison with expert recommendations from an online tool.Org: Clinical Care Options, LLC, City of Hope Comprehensive Cancer Center, University of California, San Diego Health, Division of Hematology & Oncology, University of Washington & Fred Hutchinson Cancer Center, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine,
Abstract
Clinical, environmental, genetic, and genomic profile of men with early-onset aggressive prostate cancer: A final report.Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Dana-Farber Cancer Institute, Michigan Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, MI,
Abstract
Classification of HER2 status across multiple cancers using epigenomic profiles from a novel liquid biopsy assay.Org: Precede Biosciences, Boston Pharmaceuticals, MaaT Pharma, Dana-Farber Cancer Institute, DFCI/PCC Fellowship Program - Attendings,
Abstract
A phase 1/2, open-label, multicenter, dose escalation and cohort expansion study of the safety and efficacy of anti-CD70 allogeneic CRISPR-Cas9–engineered T cells (CTX131) in adult patients with relapsed or refractory solid tumors.Org: City of Hope Comprehensive Cancer Center, Duarte, CA, Washington University School of Medicine in St Louis, St. Louis, MO, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
Young lung cancer: Psychosocial needs assessment.Org: Dana-Farber Cancer Institute, Brigham and Women's Hospital/Massachusetts General Hospital,
Abstract
Neoadjuvant immunotherapy in sarcomatoid mesothelioma (Alliance A082101).Org: Mayo Clinic, Duke University Medical Center, University of Chicago, Helen F. Graham Cancer Center and Research Institute, Newark, DE, Dana-Farber Cancer Institute,
Abstract
Disparities in patients with HER2-positive breast cancer receiving optimal treatment: Analysis of the real-world ASCO CancerLinQ dataset.Org: Brigham and Women's Hospital/Massachusetts General Hospital, Boston, MA, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX,
Abstract
Intratumoral T-cell infiltration and response to nivolumab plus ipilimumab in patients with metastatic clear cell renal cell carcinoma from the CheckMate-214 trial.Org: Brigham and Women's Hospital/Massachusetts General Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, Yale Cancer Center, Yale School of Medicine,
Abstract
Impact of cancer screening results on patient-reported outcomes (PRO) and behavioral intentions.Org: Evidera, Inc, GRAIL, LLC, a subsidiary of Illumina, Inc., Ontada, Mayo Clinic, Dana-Farber Cancer Institute,
Abstract
Acupuncture for preventing progression of taxane-induced peripheral neuropathy (ATP): A phase II randomized, placebo-controlled trial.Org: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
A randomized phase III clinical trial of acupuncture for chemotherapy-induced peripheral neuropathy treatment (ACT).Org: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
Correlation of stress, depression, sleep, and pain with race and body mass index (BMI): Secondary analysis from Alliance A011502.Org: Roswell Park Comprehensive Cancer Center, Mayo Clinic, Channing Laboratory, Johns Hopkins Kimmel Cancer Center, Sweetwater Regional Cancer Center,
Abstract
Association of a germline single nucleotide polymorphism (SNP) in the interleukin-7 (IL7) gene with immune-related adverse events (irAEs) in the CheckMate 025 trial.Org: Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Bristol Myers Squibb, The Lank Center for Genitourinary Oncology,
Clinical trial
Phase 1b Study of Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve Subjects With Acute Myelogenous LeukemiaStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
A Phase 2 Study of Neratinib With or Without Fulvestrant in HER2-Positive, ER-Positive Metastatic Breast CancerStatus: Terminated, Estimated PCD: 2021-07-20
Abstract
PD-L1 expression in pulmonary sarcomatoid carcinoma and response to immunotherapy.Org: Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology,
Abstract
Beyond the binary: A transformative implementation science initiative to improve LGBTQ+ cancer care.Org: Dana-Farber Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute, PRIME Education, LLC,
Abstract
Fostering collaborative care in multiple myeloma: The impact of holistic education on decision-making with antibody and CAR-T platforms.Org: PVI, PeerView Institute for Medical Education, HealthTree Foundation, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Cleveland Clinic Taussig Cancer Instititute,
Abstract
Molecular characterization of NUT carcinoma: A report from the NUT carcinoma registry.Org: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, Norris Comprehensive Cancer Center, University of Southern California Marshall School of Business,
Abstract
AFT-50 EndoMAP: A phase IB/II multicohort study of targeted agents and/or immunotherapy for patients with recurrent or persistent endometrial cancer (EC).Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Alliance Statistics and Data Management Center, Mayo Clinic Rochester, Rochester, MN, University of Chicago Medicine, UCSF Helen Diller Family Comprehensive Cancer Center,
Abstract
Safety outcomes in adult patients with AML who achieved their first complete remission with GO prior to HSCT.Org: H. Lee Moffitt Cancer Center and Research Institute, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Center for International Blood and Marrow Transplant Research,
Abstract
Assessing social determinants of health and optimizing resource support for patients with metastatic breast cancer: Results from the LIFT-UP study.Org: Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, NA, Dana-Farber Cancer Institute, Harvard Medical School,
Abstract
Safety and efficacy of interleukin-6 blockade for immune-related adverse events: A systematic review and meta-analysis.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Princess Margaret Cancer Centre, University Health Network, University of Toronto,
Abstract
Statistical fragility of findings from randomized phase 3 trials in pediatric oncology.Org: Boston Children's Hospital, Boston Children’s Hospital, Dana-Farber Cancer Institute, Dana-Farber/Boston Children's Cancer and Blood Disorders Center,
Abstract
Changing treatment patterns for hepatocellular carcinoma: A SEER-Medicare study.Org: Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, Dana Farber Cancer Institute, Boston, MA, Dana-Farber Cancer Institute, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Clinical trial
A Phase Ib/II Trial To Test The Safety And Efficacy Of Vaccination With HPV16-E711-19 Nanomer For The Treatment Of Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer In HLA-A*02 Positive PatientsStatus: Completed, Estimated PCD: 2019-10-04
Abstract
Predicting fitness for chemotherapy in older adults with metastatic bladder cancer.Org: Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute, Memorial Sloan Kettering Cancer Center,
Abstract
Pilot study of early integration of interventional pain management for patients with chronic cancer pain.Org: Dana-Farber Cancer Institute, Brigham and Women's Hospital/Massachusetts General Hospital,
Abstract
Correlation of circulating tumor DNA (ctDNA) dynamics with clinical response in patients with muscle-invasive bladder cancer (MIBC) undergoing trimodality therapy (TMT).Org: Dana-Farber Cancer Institute, Brigham and Women's Hospital/Massachusetts General Hospital, South Shore Health, Sturdy Health,
Clinical trial
Safety and Efficacy of Cemiplimab (PD-1 Blockade) in Selected Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma (CONTRAC)Status: Active (not recruiting), Estimated PCD: 2023-06-12
Clinical trial
A Phase Ib Study of Neoantigen Vaccine (NeoVax Plus Montanide) in Combination With Nivolumab and Locally Administered Ipilimumab in Patients With Advanced MelanomaStatus: Active (not recruiting), Estimated PCD: 2022-12-27
Abstract
Preliminary results of the Lung Cancer Mutation Consortium LCMC4 evaluation of actionable drivers in early stage lung cancer (LEADER) screening trial.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, Dana-Farber Cancer Institute, Ronald Reagan UCLA Medical Center, University of Michigan,
Abstract
Peak part 1 summary: A phase 3, randomized, open-label multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).Org: Dana-Farber Cancer Institute, Harvard Medical School, Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Miller School of Medicine, Miami, FL, Mayo Clinic Florida,
Abstract
Recurrence score gene axes scores and outcomes by race and ethnicity in the RxPONDER trial.Org: Exact Sciences Corporation, Cancer Research and Biostatistics (CRAB), Seattle, WA, ASCO, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Loyola University Chicago Stritch School of Medicine,
Abstract
Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-small cell lung cancer (NSCLC).Org: Yale New Haven Hospital, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Princess Margaret Cancer Centre, University Health Network, Massachusetts General Hospital,
Abstract
Fertility among young breast cancer survivors attempting pregnancy: A prospective, multicentre cohort study.Org: Dana-Farber Cancer Institute, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Mayo Clinic, Massachusetts General Hospital, Stanford Comprehensive Cancer Institute,
Clinical trial
A Phase 1/2 Study of Acalabrutinib in Recurrent or Refractory Central Nervous System Lymphoma (CNSL)Status: Recruiting, Estimated PCD: 2025-01-31
Abstract
Lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial.Org: University Hospital Essen, Memorial Sloan Kettering Cancer Center, Tel-Aviv Sourasky Medical Center/Tel-Aviv University, Department of Urology and Eva Mayr-Stihl Cancer Center, Klinikum Stuttgart, Stuttgart, Germany, Medical University of Vienna,
Clinical trial
Sequential Therapy With Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal CancerStatus: Completed, Estimated PCD: 2022-10-31
Clinical trial
MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Abstract
Assessing gender disparities in oncology: Less talk, more action.Org: University of Miami Sylvester Comprehensive Cancer Center, Capital Health, University of California Irvine, Mayo Clinic, Dana-Farber Cancer Institute,
Clinical trial
Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast CancerStatus: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
A Phase I Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-DiseaseStatus: Active (not recruiting), Estimated PCD: 2017-08-01
Abstract
Interpretable artificial intelligence-based analysis for morphologic classification of neuroblastic tumors.Org: University of Chicago Pritzker School of Medicine, Children's Hospital of Philadelphia, University of Chicago, Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, Stanford University Medical Center, Stanford, CA,
Clinical trial
A Phase 1b/2 Study of IPI-145 in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia.Status: Active (not recruiting), Estimated PCD: 2017-10-01
Clinical trial
A Phase 2, Two-stage, Study of Mirvetuximab Soravtansine (IMGN853) in Combination With Pembrolizumab in Patients With Microsatellite Stable (MSS) Recurrent or Persistent Endometrial Cancer (EC)Status: Active (not recruiting), Estimated PCD: 2025-08-01
Abstract
Impact of β-adrenergic blockade on efficacy of immunotherapy in patients with metastatic clear cell renal cell carcinoma.Org: Dana-Farber Cancer Institute, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, Beth Israel Deaconess Medical Center, Yale University School of Medicine, The Lank Center for Genitourinary Oncology,
Abstract
Alliance A091902: A multicenter randomized phase II trial of paclitaxel (P) with or without nivolumab (N) in patients (pts) with advanced angiosarcoma (AS).Org: Duke Cancer Institute, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Durham, NC, Mayo Clinic, Rochester, MN,
Abstract
Dual immune checkpoint inhibition with nivolumab and ipilimumab (N+I) in patients with advanced anaplastic thyroid carcinoma (ATC).Org: Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Brigham and Women's Hospital/Massachusetts General Hospital, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center,
Abstract
Botensilimab plus balstilimab in microsatellite stable metastatic colorectal cancer: Assessing efficacy in non-liver metastatic sites.Org: Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, Beth Israel Deaconess Medical Center, Boston, MA,
Abstract
Association of body mass index (BMI) with survival outcomes in patients with metastatic renal cell carcinoma (mRCC).Org: Emory Winship Cancer Institute, Winship Cancer Institute of Emory University, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Emory University School of Medicine, Emory University, Atlanta, GA, USA,
Abstract
Investigation of T cell phenotypes associated with response or resistance to immune checkpoint inhibitors (ICI) through single-cell analysis of renal cell carcinoma (RCC).Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, Yale School of Medicine, Brigham and Women's Hospital/Massachusetts General Hospital, Dana-Farber Cancer Institute, The Lank Center for Genitourinary Oncology,
Abstract
Survival in de novo metastatic merkel cell carcinoma according to sites of metastases.Org: Dana-Farber Cancer Institute, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, Department of Data Sciences, Dana Farber Cancer Institute, Boston, MA, Harvard Medical School,
Clinical trial
ATOP TRIAL: Adjuvant Ado-Trastuzumab Emtansine (T-DM1) for Older Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerStatus: Active (not recruiting), Estimated PCD: 2026-08-30
Clinical trial
Phase 1 Trial of Marizomib Alone and in Combination With Panobinostat for Children With Diffuse Intrinsic Pontine GliomaStatus: Terminated, Estimated PCD: 2024-02-14
Clinical trial
A Phase 2 Trial of Zanubrutinib and Venetoclax in Previously Treated CLL/SLL PatientsStatus: Recruiting, Estimated PCD: 2025-10-28
Clinical trial
A Phase II Study of Atezolizumab in Combination With Stereotactic Radiation for Patients With Triple-negative Breast Cancer and Brain MetastasisStatus: Active (not recruiting), Estimated PCD: 2019-11-21
Clinical trial
A Phase II Study Evaluating Venetoclax and Pirtobrutinib in Previously Treated Waldenström MacroglobulinemiaStatus: Recruiting, Estimated PCD: 2029-01-25
Clinical trial
INTREPId (INTermediate Risk Erection PreservatIon Trial): A Randomized Trial of Radiation Therapy and Darolutamide for Prostate CancerStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Phase II Randomized Study Of Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide For Intermediate-High Risk Prostate Cancer Undergoing ProstatectomyStatus: Active (not recruiting), Estimated PCD: 2023-05-01
Clinical trial
A Phase Ib Study of the Combination of Venetoclax With Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory Acute Lymphoblastic LeukemiaStatus: Recruiting, Estimated PCD: 2026-04-30
Clinical trial
A Phase 1 Trial of CTLA-4 Inhibition, With or Without Cetuximab, and in Combination With Memory-like Natural Killer (NK) Cell Immune Cell Therapy in Advanced Head & Neck CancerStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase II Study of Lenalidomide for Adult Histiocyte DisordersStatus: Active (not recruiting), Estimated PCD: 2024-02-01
Clinical trial
A Randomized, Controlled Phase II Surgical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters for the Viral Cancer Therapy Ofranergene Obadenovec (VB-111) in Patients With Surgically Accessible Recurrent/Progressive GlioblastomaStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Phase 1 Study of Combination Nivolumab and Ipilimumab With Irradiated GM-CSF Secreting Autologous Neuroblastoma Cell Vaccine (GVAX) for Relapsed or Refractory NeuroblastomaStatus: Active (not recruiting), Estimated PCD: 2027-01-01
Clinical trial
Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related DisordersStatus: Active (not recruiting), Estimated PCD: 2020-01-01
Clinical trial
A Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast CancerStatus: Active (not recruiting), Estimated PCD: 2016-06-01
Clinical trial
A Phase 2 Study of Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast CancerStatus: Terminated, Estimated PCD: 2021-08-18
Clinical trial
A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) BiomarkerStatus: Completed, Estimated PCD: 2019-01-01
Clinical trial
Phase I Trial of Ribociclib in Combination With Everolimus and Dexamethasone in Children and Young Adults With Relapsed Acute Lymphoblastic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2023-03-04
Clinical trial
A Pilot Study of a Personalized Neoantigen Cancer Vaccine With and Without Low-Dose Cyclophosphamide or Pembrolizumab in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated Chronic Lymphocytic Leukemia.Status: Recruiting, Estimated PCD: 2026-03-31
Clinical trial
A Phase Ib Study of Ibrutinib in Combination With Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2020-03-01
Clinical trial
A Phase 2, Two-Group, Two-Stage, Open-Label Study of Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer, Avelumab / Talazoparib in Patients With MSS Recurrent or Persistent Endometrial Cancer, and Avelumab / Axitinib in Patients With MSS Recurrent or Persistent Endometrial CancerStatus: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
Phase 2 Proof of Concept Study of Nivolumab and Ipilimumab in Children and Young Adults With Relapsed or Refractory INI1-negative CancersStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase II Study of Niraparib With Dostarlimab Therapy as Neoadjuvant Treatment for Patients With BRCA-mutated Breast CancerStatus: Recruiting, Estimated PCD: 2025-07-17
Clinical trial
Phase II Clinical Trial of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer With Correlative Assessment of Hormone Intermediates.Status: Active (not recruiting), Estimated PCD: 2021-12-01
Clinical trial
NIMBUS: A Phase II Study of Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2021-09-30
Clinical trial
A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine CarcinosarcomaStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Biology of Young Lung Cancer Study: The YOUNG LUNG StudyStatus: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
Randomized, Double-blind Phase II Study of a Single Dose of Cannabidiol (CBD) for Acute Anticipatory Anxiety in Advanced Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Pilot/Phase 1 Study of Immunosuppression-free Regulatory T-cell Graft-engineered Haploidentical Hematopoietic Cell Transplantation in Relapsed/Refractory and Ultra-High-risk AML/MDSStatus: Recruiting, Estimated PCD: 2025-10-31
Clinical trial
A Single Arm Phase 2 Trial of Atezolizumab With Sacituzumab Govitecan to Prevent Recurrence in Triple Negative Breast Cancer (ASPRIA)Status: Active (not recruiting), Estimated PCD: 2025-12-30
Clinical trial
A Phase 2 Study of Eribulin Followed by Doxorubicin and Cyclophosphamide as Preoperative Therapy for HER2-negative Inflammatory Breast CancerStatus: Active (not recruiting), Estimated PCD: 2021-05-01
Clinical trial
A Phase Ib/II Study of Pembrolizumab, Ibrutinib and Rituximab in Refractory/Relapsed Primary Central Nervous System Lymphoma (PCNSL)Status: Recruiting, Estimated PCD: 2024-08-05
Clinical trial
A Phase I/IB Trial of Abemaciclib Alone or in Combination With MK-6482 in Advanced Renal Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Randomized Phase III Study - Conventional Androgen Deprivation Therapy With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and Androgen Deprivation TherapyStatus: Terminated, Estimated PCD: 2024-02-13
Clinical trial
A Pilot Study for Detection of PSMA-Low Castration Resistant and Neuroendocrine Prostate Cancer With 18F-fluciclovine PET/CT ImagingStatus: Not yet recruiting, Estimated PCD: 2026-09-01
Clinical trial
A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive LymphomasStatus: , Estimated PCD: 2022-08-18
Clinical trial
Venetoclax Plus Dose-adjusted R-EPOCH or R-CHOP for Richter's SyndromeStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous LeukoplakiaStatus: Active (not recruiting), Estimated PCD: 2022-09-01
Clinical trial
Pilot Trial of Olaparib in Patients With Unresectable or Metastatic Melanoma With Mutations in BRCA1/2 GenesStatus: Withdrawn, Estimated PCD: 2026-05-01
Clinical trial
An Open-Label, Single Arm, Phase 2a Study of Bortezomib, Lenalidomide, Dexamethasone and Elotuzumab in Newly Diagnosed Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2021-12-15
Clinical trial
Phase II Trial of Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent GlioblastomaStatus: Active (not recruiting), Estimated PCD: 2021-12-09
Clinical trial
A Phase 2 Pilot Feasibility Study of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive Invasive Breast CarcinomaStatus: Completed, Estimated PCD: 2018-05-01
Clinical trial
Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS): A Randomized Phase II Study of Palbociclib With Letrozole Versus Letrozole Alone for Invasive Lobular Carcinoma and Invasive Ductal CarcinomaStatus: Active (not recruiting), Estimated PCD: 2022-02-01
Clinical trial
Phase II Trial of Cabozantinib in Combination With Nivolumab for Advanced Carcinoid TumorsStatus: Completed, Estimated PCD: 2023-12-27
Clinical trial
Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens From Children And Young Adults With Hematologic MalignancyStatus: Recruiting, Estimated PCD: 2033-06-01
Clinical trial
Nano-SMART: An Adaptive Phase I-II Trial of AGuIX Gadolinium-based Nanoparticles With Stereotactic Magnetic Resonance-guided Adaptive Radiation Therapy for Centrally Located Lung Tumors and Locally Advanced Unresectable Pancreatic Ductal AdenocarcinomaStatus: Recruiting, Estimated PCD: 2026-04-10
Clinical trial
A Phase 0/2 Study of Abemaciclib in Recurrent GlioblastomaStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Randomized Phase 2 Study to Examine the Impact of Gut Decontamination on Intestinal Microbiome Composition in Pediatric Allogeneic Hematopoietic Stem Cell Transplant PatientsStatus: Completed, Estimated PCD: 2021-04-15
Clinical trial
A Phase II Study of Ofatumumab-High Dose Methylprednisolone Followed by Ofatumumab-Alemtuzumab in 17p Deletion CLLStatus: Terminated, Estimated PCD: 2014-11-01
Clinical trial
Phase II Protocol Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the BoneStatus: Active (not recruiting), Estimated PCD: 2022-05-01
Clinical trial
Vitamin D Receptor Agonist Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Patients With Metastatic Pancreatic CancerStatus: Active (not recruiting), Estimated PCD: 2023-09-01
Clinical trial
Phase II Trial of Paclitaxel Combined With Trastuzumab and Pertuzumab as Pre-Operative Therapy for Inflammatory Breast CancerStatus: Active (not recruiting), Estimated PCD: 2018-06-01
Clinical trial
DAPHNe: De-escalation to Adjuvant Antibodies Post-pCR to Neoadjuvant THP (Paclitaxel/Trastuzumab/Pertuzumab)-a Pilot Study in HER2-positive Breast CancerStatus: Active (not recruiting), Estimated PCD: 2020-10-08
Clinical trial
Preventative Skin Care for Children Undergoing Targeted CNS Tumor TherapyStatus: Active (not recruiting), Estimated PCD: 2024-01-01
Clinical trial
A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2021-12-01
Clinical trial
Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid TumorsStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid TumorStatus: Active (not recruiting), Estimated PCD: 2025-02-28
Clinical trial
A Randomized Phase 2 Study of Obinutuzumab for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Peripheral Blood Stem Cell TransplantationStatus: Active (not recruiting), Estimated PCD: 2023-11-29
Clinical trial
ALL Adult Consortium Trial: Adult ALL TrialStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
An Open-Label Phase I/II Study of the Safety and Efficacy of Bortezomib, Lenalidomide and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2009-07-01
Clinical trial
Li-Fraumeni & TP53: Understanding and Progress (LiFT UP)Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory Chronic Graft-versus-Host-DiseaseStatus: Active (not recruiting), Estimated PCD: 2017-08-01
Clinical trial
A Phase II Trial of Daily Low-Dose Interleukin-2 (IL-2) for Steroid-Refractory Chronic Graft-Versus-Host-DiseaseStatus: Active (not recruiting), Estimated PCD: 2014-10-01
Clinical trial
A Phase II Study of Adjuvant Ado-trastuzumab Emtansine (T-DM1) in HER2-positive Salivary Gland CarcinomasStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Pilot Study of a Personalized Neoantigen Cancer Vaccine in Combination With Pembrolizumab Following Front-Line Rituximab in Follicular LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-02-20
Clinical trial
Sacituzumab Govitecan Plus Enfortumab Vedotin for Metastatic Urothelial Carcinoma Progressing on Platinum-based Chemotherapy and PD1/L1 Inhibitors: the Double Antibody Drug Conjugate (DAD) Phase I TrialStatus: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
A Phase II Multi-Center Trial of Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-20
Clinical trial
A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary TumorsStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Hereditary Risk Factors for Thyroid CancerStatus: Recruiting, Estimated PCD: 2029-03-01
Clinical trial
A Phase II Study of BVD-523 in Metastatic Uveal MelanomaStatus: Active (not recruiting), Estimated PCD: 2020-05-05
Clinical trial
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid TumorsStatus: Active (not recruiting), Estimated PCD: 2022-12-31
Clinical trial
Phase II Trial of Olaparib in Combination With Ceralasertib in Patients With Recurrent OsteosarcomaStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase I Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2, a Genetically Engineered HSV-1 Virus, and Immunomodulation With CyclophosphamideStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Double-blind, Phase II Randomized Study of Brain-directed Stereotactic Radiation With or Without AGuIX Gadolinium-based Nanoparticles in the Management of Brain Metastases at Higher Risk of Local Recurrence With Radiation AloneStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Phase II Study on the Combination of Ibrutinib and Venetoclax in Treatment naïve Patients With Waldenström MacroglobulinemiaStatus: Active (not recruiting), Estimated PCD: 2022-06-06
Clinical trial
A Phase IB Study of Vaccination With Autologous, Lethally Irradiated Melanoma Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Human Granulocyte-Macrophage Stimulating FactorStatus: Active (not recruiting), Estimated PCD: 2016-09-01
Clinical trial
A Phase II Trial of Ipilimumab With and Without Nivolumab in Patients With Relapsed/Refractory Classic Hodgkin LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
An Open-Label, Phase II Study of Cabozantinib (XL184) in Advanced Pancreatic Neuroendocrine and Carcinoid TumorsStatus: Completed, Estimated PCD: 2021-08-01
Clinical trial
Phase I Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and NeckStatus: Active (not recruiting), Estimated PCD: 2021-01-01
Clinical trial
Phase II Trial of CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric CancerStatus: Active (not recruiting), Estimated PCD: 2021-12-01
Clinical trial
A Phase 2 Study of Preoperative Pembrolizumab and Chemotherapy Followed by Adjuvant Pembrolizumab in Resectable Locoregionally Recurrent Head and Neck Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2025-05-20
Clinical trial
Phase II Trial of GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain MetastasesStatus: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
Multicenter Cohort Study To Evaluate Outcomes After Receipt of Targeted Therapy Matched to an Individualized Cancer Therapy (iCat) Recommendations in Children and Young Adults With Solid Tumors: The iCat2, GAIN Consortium StudyStatus: Active (not recruiting), Estimated PCD: 2024-01-01
Clinical trial
A Phase 2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) for Initial Therapy of Chronic Lymphocytic LeukemiaStatus: Active (not recruiting), Estimated PCD: 2024-04-10
Clinical trial
Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver MalignanciesStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Investigating Hereditary Risk In Thoracic Cancers (INHERIT)Status: Recruiting, Estimated PCD: 2027-11-01
Clinical trial
RESOLVE: letRozole abEmaciclib combinationS in endOmetriaL and oVarian cancEr: A Multi-Cohort Phase 2 Study of Letrozole/Abemaciclib Alone and in Combination With Metformin and ZotatifinStatus: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
A Randomized Phase II Study Of Eribulin Mesylate With Or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast CancerStatus: Completed, Estimated PCD: 2018-10-11
Clinical trial
A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast CancerStatus: Completed, Estimated PCD: 2014-04-21
Clinical trial
A Phase Ia/Ib Study of Talazoparib in Combination With Tazemetostat in Metastatic Castration-resistant Prostate Cancer (mCRPC)Status: Active (not recruiting), Estimated PCD: 2025-03-30
Clinical trial
A Randomized Phase II Trial of Adjuvant Trastuzumab Emtansine (T-DM1) Followed by Subcutaneous Trastuzumab Versus Paclitaxel in Combination With Subcutaneous Trastuzumab for Stage I HER2-positive Breast Cancer (ATEMPT 2.0)Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell TransplantationStatus: , Estimated PCD: 2024-12-01
Clinical trial
A Phase II Study of Merestinib in Non-Small Cell Lung Cancers Harboring MET Exon 14 Mutations and Solid Tumors With NTRK RearrangementsStatus: Terminated, Estimated PCD: 2021-10-01
Clinical trial
RecoverPC: A Phase 2 Study of RElugolix Versus GnRH Agonist Quality of Life (QOL) and Testosterone reCOVERy in Men With Prostate CancerStatus: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase I Trial of Vaccination With Lethally Irradiated Lymphoma Cells Admixed With Granulocyte-Macrophage Colony Stimulating Factor Secreting K562 Cells for the Treatment of Previously Untreated or Relapses Follicular LymphomaStatus: Active (not recruiting), Estimated PCD: 2023-07-01
Clinical trial
A Phase II Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL)Status: Active (not recruiting), Estimated PCD: 2024-01-01
Clinical trial
A Blinded, Randomized Phase 2 Study of Troriluzole in Combination With Ipilimumab and Nivolumab in Patients With Melanoma Brain Metastases Previously Treated With Anti-PD-1 TherapyStatus: Terminated, Estimated PCD: 2023-05-29
Clinical trial
A Pilot Study of 18Fluorine-Fluciclovine Positron Emission Tomography/Computed Tomography for Staging Muscle Invasive Bladder Cancer Preceding Radical CystectomyStatus: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Phase II Study of Ziv-aflibercept in Patients With Advanced, Progressive Carcinoid TumorsStatus: Completed, Estimated PCD: 2021-03-01
Clinical trial
Phase II Clinical Trial of Rosiglitazone, a Full-Agonist Ligand for the Peroxisome Proliferator-Activated Receptor Gamma (PPAR), as Differentiation Therapy for Patients With LiposarcomaStatus: Completed, Estimated PCD: 2006-03-01
Clinical trial
Phase 1 Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Status: Active (not recruiting), Estimated PCD: 2025-01-19
Clinical trial
NeoVax With Nivolumab in Patients With Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2025-04-30
Clinical trial
A Multicenter Phase 2 Clinical Trial of Pembrolizumab in Metastatic Anal CancerStatus: Completed, Estimated PCD: 2021-12-01
Clinical trial
A Randomized, Phase II Study Evaluating the Addition of Pembrolizumab (MK-3475) to Radium-223 in Metastatic Castration Resistant Prostate Cancer (mCRPC)Status: Active (not recruiting), Estimated PCD: 2020-04-09
Clinical trial
E- PRISM: Precision Intervention Smoldering Myeloma: Phase II Trial of Combination of Elotuzumab, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple MyelomaStatus: Completed, Estimated PCD: 2018-12-12
Clinical trial
Matched Targeted Therapy (MTT) Recommendation for Patients With Recurrent, Refractory, or High Risk Leukemias and Myelodysplastic SyndromeStatus: Active (not recruiting), Estimated PCD: 2022-05-16
Clinical trial
Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric CancerStatus: Completed, Estimated PCD: 2023-07-17
Clinical trial
The TRADE Study: A Phase 2 Trial to Assess the ToleRability of Abemaciclib Dose Escalation in Patients With Early-Stage HR-positive and HER2-negative Breast CancerStatus: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
A Pilot Proof-of-Concept Study of Talazoparib-Based Therapy for Cohesin-Mutated AML and MDS With Excess BlastsStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and NeckStatus: Active (not recruiting), Estimated PCD: 2021-07-06
Clinical trial
A Phase I Trial of Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV MelanomaStatus: Completed, Estimated PCD: 2018-06-22
Clinical trial
A Feasibility Trial of Everolimus (RAD001),an mTOR Inhibitor, Given in Combination With Multiagent Re-Induction Chemotherapy in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia (ALL)Status: Completed, Estimated PCD: 2017-01-01
Clinical trial
Biomarkers of Response to Ipilimumab and Nivolumab as First-line Therapy for Metastatic Non-small Cell Lung Cancer (NSCLC): an Open-label, Single Arm Phase 2 StudyStatus: , Estimated PCD: 2020-05-18
Clinical trial
CAR- PRISM (PRecision Intervention Smoldering Myeloma): A Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in High-Risk Smoldering MyelomaStatus: Recruiting, Estimated PCD: 2026-01-15
Clinical trial
Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA After Radical Prostatectomy With Adverse Features.(FORMULA-509 Trial)Status: Active (not recruiting), Estimated PCD: 2025-04-05
Clinical trial
A Phase I Study of a Personalized NeoAntigen Cancer Vaccine With Radiotherapy Plus Pembrolizumab/MK-3475 Among Newly Diagnosed Glioblastoma PatientsStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Study to Identify Transcriptional Targets of Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases Receiving Preoperative Vitamin D Supplementation.Status: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
Pilot Study of Perampanel on Peritumoral Hyperexcitability and Seizure Control in Newly Diagnosed High Grade GliomaStatus: Completed, Estimated PCD: 2023-05-16
Clinical trial
Copy of A Phase II Trial of Pembrolizumab (Anti PD-1) Therapy Combined With Sargramostim (GM-CSF) in Unresectable or Metastatic MelanomaStatus: Withdrawn, Estimated PCD: 2024-06-10
Clinical trial
20-347 NCT Number Title A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (ADEPT)Status: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer (TNBC)Status: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Participants With Brain Metastases From HER2+ Breast CancerStatus: Completed, Estimated PCD: 2018-03-01
Clinical trial
A Phase 1 Study of Durvalumab, Tremelimumab and Radiotherapy in Recurrent Gynecologic CancerStatus: Terminated, Estimated PCD: 2022-07-15
Clinical trial
An Open-Label Phase II Study of Nivolumab in Adult Participants With Progressive/Recurrent MeningiomaStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Phase II Trial of the PD-1 Antibody Nivolumab in Combination With Lenalidomide and Low Dose Dexamethasone in Patients With High-Risk Smoldering Multiple MyelomaStatus: Completed, Estimated PCD: 2018-06-28
Clinical trial
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk IndividualsStatus: Recruiting, Estimated PCD: 2040-10-31
Clinical trial
A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer: The SAPPHO Study:Status: Not yet recruiting, Estimated PCD: 2030-03-30
Clinical trial
A Phase 1/2 Study of Osimertinib in Combination With Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerStatus: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
A Clinical Trial to Evaluate Image-Guided Gynecologic Brachytherapy in the Advanced Multimodality Image-Guided Operating Suite (AMIGO)Status: Completed, Estimated PCD: 2016-02-01
Clinical trial
A Phase I Study of Anti-CD19 CAR T-cell Therapy With Axicabtagene Ciloleucel (Axi-cel) in Patients With Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral CavityStatus: Active (not recruiting), Estimated PCD: 2019-07-01
Clinical trial
A Phase II Study of CHOEP Induction Followed by Gemcitabine/Busulfan/Melphalan Autologous Stem Cell Transplantation for Patients With Newly Diagnosed T-Cell LymphomaStatus: Terminated, Estimated PCD: 2014-10-01
Clinical trial
Phase 2, Randomized, Trial of Maintenance Letrozole/Abemaciclib vs Pembrolizumab After Systemic Therapy in Patients With Advanced or Recurrent Estrogen Receptor Positive, Mismatch Repair Proficient, TP53 Wild-type Endometrial CancerStatus: Not yet recruiting, Estimated PCD: 2027-09-01
Clinical trial
LuCarbo - a Phase 1a/1b Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate CancerStatus: Recruiting, Estimated PCD: 2026-07-19
Clinical trial
A Phase 1 Study of Cytokine-induced Memory-like (CIML) NK Cells With Venetoclax as Consolidation Therapy in AMLStatus: Active (not recruiting), Estimated PCD: 2026-11-30
Clinical trial
A Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2026-10-04
Clinical trial
A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal CarcinomaStatus: Completed, Estimated PCD: 2012-03-01
Clinical trial
Phase 2 Trial of Palbociclib and Ganitumab in Patients With Relapsed or Refractory Ewing SarcomaStatus: Completed, Estimated PCD: 2022-12-15
Clinical trial
A Phase 2 Study of Pembrolizumab (MK-3475) After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma and, Diffuse Large B Cell Lymphoma and T- Cell Non-Hodgkin LymphomaStatus: Completed, Estimated PCD: 2021-10-26
Clinical trial
A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin LymphomaStatus: Completed, Estimated PCD: 2019-07-11
Clinical trial
Phase 1 Study of Cabozantinib in Combination With Topotecan-Cyclophosphamide for Patients With Relapsed Ewing Sarcoma or OsteosarcomaStatus: Completed, Estimated PCD: 2022-10-24
Clinical trial
Phase 1 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Phase Ib Study of NeoVax in Combination With CDX-301 and Nivolumab or Pembrolizumab and in Patients With MelanomaStatus: Recruiting, Estimated PCD: 2025-01-31
Clinical trial
Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Ovarian, Fallopian Tube, and Peritoneal CancerStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase I/II Study of Pyrimethamine, a STAT3 Inhibitor, for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaStatus: Completed, Estimated PCD: 2022-02-01
Clinical trial
A Phase 2 Study of Avelumab in Combination With Bladder-Directed Radiation in Cisplatin-Ineligible Patients With Muscle-Invasive Urothelial Carcinoma of the BladderStatus: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
A Phase 1 Study of Venetoclax in Combination With Inotuzumab Ozogamicin for B-cell Acute Lymphoblastic Leukemia (B-ALL)Status: Recruiting, Estimated PCD: 2024-07-23
Clinical trial
A Phase 2 Study of Eribulin in Patients With HER2-Negative, Metastatic Breast Cancer: Evaluation of Efficacy, Toxicity and Patient-Reported OutcomesStatus: Completed, Estimated PCD: 2016-05-01
Clinical trial
A Phase 2 Study of Nivolumab Plus Ipilimumab in RAI Refractory, Aggressive Thyroid Cancer With Exploratory Cohorts in Medullary and Anaplastic Thyroid CancerStatus: Active (not recruiting), Estimated PCD: 2021-01-21
Clinical trial
Cabozantinib in Recurrent/Metastatic Merkel Cell CarcinomaStatus: Terminated, Estimated PCD: 2016-04-01
Clinical trial
Phase II Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple MyelomaStatus: Active (not recruiting), Estimated PCD: 2025-04-08
Clinical trial
Cytokine-induced Memory-like Natural Killer Cell Therapy After Hematopoietic Stem Cell Transplantation for Eradication of Measurable Residual Disease, a Phase I/Ib Clinical TrialStatus: Recruiting, Estimated PCD: 2026-02-28
Clinical trial
A Phase 2 Study With Safety Run-In of Marizomib, Pomalidomide, and Dexamethasone For Relapsed and Refractory Multiple Myeloma and CNS MyelomaStatus: Not yet recruiting, Estimated PCD: 2025-12-02
Clinical trial
A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination With Ibrutinib in Patients With Select B-Cell MalignanciesStatus: Completed, Estimated PCD: 2018-05-01
Clinical trial
An Open-Label, Phase 2 Study to Evaluate the Activity of Belumosudil in Subjects With New Onset and Incipient Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell TransplantationStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase I Study of Afatinib With Postoperative Radiation Therapy for Intermediate and High Risk Squamous Cancer of the Head and Neck (SCCHN)Status: Completed, Estimated PCD: 2017-11-20
Clinical trial
Enzalutamide With External Beam Radiation for Intermediate Risk Prostate Cancer: A Phase II StudyStatus: Completed, Estimated PCD: 2017-10-01
Clinical trial
A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium ProtocolStatus: Active (not recruiting), Estimated PCD: 2024-01-01
Clinical trial
A Phase II Trial of HKI-272 (Neratinib), Neratinib and Capecitabine, and Ado-Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain MetastasesStatus: Active (not recruiting), Estimated PCD: 2023-02-01
Abstract
First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy.Org: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, Sarah Cannon Research Institute/Tennessee Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Pfizer, Inc.,
Abstract
NCCTG N1174: Phase I/comparative randomized phase (Ph) II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma (GBM) (Alliance).Org: Mayo Clinic, Alliance Statistics and Data Center, University of California Irvine, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, University of Virginia Health System,
Abstract
Cemiplimab for kidney organ transplant recipients with advanced cutaneous squamous cell carcinoma: CONTRAC-1.Org: Dana-Farber Cancer Institute, Tufts Medical Center/Tufts University, Maine Medical Center Research Institute, Brigham and Women's Hospital/Massachusetts General Hospital, Brigham and Women's Faulkner Hospital,
Abstract
Quality and accessibility of liquid biopsy information: An analysis of online content.Org: University of California, San Francisco, Division of Endocrinology, San Francisco, CA, Dana-Farber Cancer Institute, Harvard Medical School, University of California San Francisco,
Abstract
Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses.Org: Dana-Farber Cancer Institute, Mayo Clinic, Harvard Medical School, Brigham and Women's Hospital/Massachusetts General Hospital, National Cancer Institute, Vilnius, Lithuania,
Abstract
Real-world outcomes with novel therapies in R/R DLBCL.Org: Dana-Farber Cancer Institute, Genmab US, Inc., AbbVie Inc., North Chicago, IL,
Abstract
EphrinB2 (B2) expression predicts poor response to PD1/L1 antibodies (Ab) in metastatic urothelial carcinoma (mUC).Org: University of Southern California Marshall School of Business, Vasgene Therapeutics, Inc, Rutgers University, Dana-Farber Cancer Institute, University of Colorado Cancer Center Anschutz Medical Campus,
Abstract
A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors.Org: Memorial Sloan Kettering Cancer Center, Stanford University Medical Center, Stanford, CA, Seoul National University Bundang Hospital, START Midwest, Grand Rapids, MI, Samsung Medical Center,
Abstract
SAVE (Safe Accelerated Venetoclax Escalation): Initial results of a prospective, phase Ib study of venetoclax with an accelerated dose ramp-up in patients with CLL.Org: Dana-Farber Cancer Institute, Department of Data Sciences, DFCI/PCC Fellowship Program - Attendings,
Abstract
Role of nivolumab maintenance therapy in advanced melanoma patients following severe immune-related adverse events from combination nivolumab and ipilimumab.Org: Frank H Netter MD School of Medicine, Dana-Farber Cancer Institute, Quinnipiac University, Dana-Farber Cancer Institute and Harvard Medical School,
Abstract
Investigation into aberrant B cell repertoire in myeloma on humoral immunity and patient survival.Org: Wayne State Univ/DMC Sinai Grace Hospital, Dana-Farber Cancer Institute, Boston University Medical Center, Hematology Department, Hospital Universitari i Politècnic La Fe, University Hospital of Santa Maria,
Abstract
Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL).Org: Dana-Farber Cancer Institute, Gilead, Stanford University School of Medicine, City of Hope National Medical Center, The University of Kansas Medical Center,
Abstract
Strategies to increase accrual of underrepresented populations in Alliance NCTN trials.Org: The Ohio State University - James Cancer Hospital, Columbus, OH, Alliance NCTN Foundation, Chicago, IL, University of Colorado Denver Anschutz Medical Center,
Abstract
End-of-life spending analysis of randomized trial of machine learning nudges to prompt serious illness communication among patients with cancer.Org: Perelman School of Medicine, University of Pennsylvania, Ascension Health, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Dana-Farber Cancer Institute,
Abstract
A phase I trial of palbociclib (palbo) and bosutinib (bos) with fulvestrant (fulv) in patients (pts) with hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) refractory to an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i).Org: Medstar Georgetown University Hospital-Lombardi Comprehensive Cancer Center, Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University, Dana-Farber Cancer Institute, AstraZeneca, Lombardi Comprehensive Cancer Center, Georgetown University,
Abstract
A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors.Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, NEXT Oncology - Virginia Cancer Specialists, University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute,
Abstract
Preclinical and early clinical data of ZN-1041 in combination with trastuzumab deruxtecan to treat breast cancer with or without CNS metastases.Org: Duke Cancer Institute, Dana-Farber Cancer Institute, The Oncology Institute of Hope and Innovation, Suzhou Zanrong Pharma,
Abstract
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair–proficient (MMR-P) recurrent or persistent endometrial cancer (EC).Org: Medical Oncology Group, Dana-Farber Cancer Institute, Boston Pharmaceuticals, MaaT Pharma, Dana-Farber Cancer Institute/Harvard Cancer Center, Boston, MA,
Abstract
A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor–positive (ER+)/HER2-negative (HER2-) breast cancer.Org: University of Colorado Cancer Center, Breast Cancer Research Centre - WA & Curtin University, Dana-Farber Cancer Institute, Olema Oncology, AdventHealth Orlando,
Abstract
Phase I/II study of stereotactic radiosurgery with concurrent olaparib followed by adjuvant durvalumab and physician’s choice systemic therapy in patients with breast cancer brain metastases.Org: University of North Carolina at Chapel Hill, Memorial Sloan Kettering Cancer Center, University of North Carolina School of Medicine, Lineberger Comprehensive Cancer Center, Dana-Farber Cancer Institute,
Abstract
Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial.Org: Dana-Farber Cancer Institute, Harvard Medical School, Inova Schar Cancer Institute, Instituto Valenciano de Oncología, Princess Margaret Cancer Centre,
Abstract
A phase 1/2 study of CFT1946, a novel, bifunctional degradation activating compound (BIDAC) degrader, of mutant BRAF V600 as monotherapy and in combination with trametinib, in mutant BRAF V600 solid tumors.Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Virginia Cancer Specialists, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
AFT-50 EndoMAP: A phase IB/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer.Org: Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, University of Chicago, Chicago, IL,
Abstract
Core biopsy (bx) accuracy and safety of biopsy and preoperative immunotherapy in predicting histological subtype and nuclear grade in ECOG-ACRIN EA8143 perioperative nivolumab (nivo) versus observation in patients (pts) with renal cell carcinoma (RCC) undergoing nephrectomy.Org: Perelman School of Medicine, University of Pennsylvania, Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center,
Abstract
First-in-human phase 1/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer.Org: Stephenson Cancer Center, University of Oklahoma Health Sciences Center/Sarah Cannon Research Institute, Massachusetts General Hospital, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC,
Abstract
Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma.Org: Fred Hutchinson Cancer Research Center, Boston University Medical Center, Massachusetts General Hospital, Dana-Farber Cancer Institute, Medical College of Wisconsin,
Abstract
Patient reported quality of life (QOL) and survival outcomes: Analysis of ECOG-ACRIN E3805 chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PCa).Org: Beth Israel Deaconess Medical Center, Dana Farber Cancer Institute, Boston, MA, ECOG-ACRIN Biostatistics Center, University of Wisconsin Hospital and Clinics, Johns Hopkins Kimmel Cancer Center,
Abstract
Not all treated KRAS-mutant pancreatic adenocarcinomas are equal: KRAS G12D and survival outcome.Org: Sylvester Comprehensive Cancer Center, Miami, FL, University of Maryland Capital Region, Caris Life Sciences, Irving, TX, Hoag Memor Hosp, University of Kansas Cancer Center, Kansas City, KS,
Abstract
Large-scale clinicogenomic models of solid tumor CNS metastasis.Org: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute,
Abstract
Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC).Org: Prostate Cancer Foundation, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Mayo Clinic,
Abstract
To test, or not to test, that is the question: A real-world analysis of PD-L1 expression testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).Org: Merck & Co., Inc., Dana-Farber Cancer Institute,
Abstract
ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer (TNBC) and residual disease after neoadjuvant therapy (NAT) and surgery.Org: Dana-Farber Cancer Institute, University of Pennsylvania, The Cancer Institute Hospital of JFCR, Tokyo, Japan, University of California Comprehensive Cancer Center, University of North Carolina at Chapel Hill,
Abstract
A phase II study of nivolumab and ipilimumab with radiation therapy in patients with metastatic, microsatellite stable pancreatic adenocarcinoma.Org: Harvard Radiation Oncology Program, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School,
Abstract
A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.Org: Dana-Farber Cancer Institute, Bristol Myers Squibb, Institute for Myeloma and Bone Cancer Research, Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, Catalan Institute of Oncology and Josep Carreras Institute,
Abstract
Characterizing progression to subsequent lines of therapy in metastatic renal cell carcinoma (mRCC) after nivolumab plus ipilimumab (Nivo+Ipi): Results from the International mRCC Database Consortium (IMDC).Org: Tom Baker Cancer Centre, University of Calgary, BC Cancer Agency Vancouver Island Centre, University Hospital of Southern Denmark, University of Bari 'A. Moro',
Abstract
Assessing tumor-infiltrating immune cells and outcomes with cisplatin- versus carboplatin-based treatment in advanced urothelial cancer (UC): Survival analysis of three platinum-treated UC cohorts.Org: Medical University of Lodz, Lodz, Poland, PSMAR Hospital del Mar Medical Research Institute (IMIM), Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Dana-Farber Cancer Institute,
Abstract
Phase 1 study of WNT pathway Porcupine inhibitor CGX1321 and phase 1b study of CGX1321 + pembrolizumab (pembro) in patients (pts) with advanced gastrointestinal (GI) tumors.Org: Dana-Farber Cancer Institute, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Georgetown University Hospital, Washington, DC, Lombardi Comprehensive Cancer Center, START San Antonio,
Abstract
ESR1 mutational landscape and impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, Guardant Health, Inc., Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA).Org: Dana-Farber Cancer Institute, Alliance Statistics and Data Management Center, Mayo Clinic, University of Nebraska Medical Center, Sanford Health,
Abstract
A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a single agent and in combination therapy in participants 16 years and older with advanced solid tumors with BRAF alterations.Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Henry Ford Cancer Institute, Detroit, MI, University of Colorado Denver Anschutz Medical Center, Dana-Farber Cancer Institute,
Abstract
Disease-free survival (DFS) as a surrogate for overall survival (OS) in patients (pts) with HR+/HER2− early breast cancer (EBC): A correlation analysis.Org: Helios Klinikum Berlin-Buch, Dana-Farber Cancer Institute, International Breast Cancer Center, Quiron Group, Practice for Hematology and Internal Oncology, Latin American Cooperative Oncology Group (LACOG),
Abstract
The relationship between a priori defined prognostic risk groups and and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC).Org: Duke University Medical Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, MRC Clinical Trials Unit at UCL, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, SWOG Statistical Center,
Abstract
Updated results from an ongoing phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via IT injection as monotherapy or combined with pembrolizumab in advanced solid tumors.Org: Banner MD Anderson Cancer Center, Massachusetts General Hospital, Southern Oncology Clinical Research Unit Pty Ltd., Alfred Hospital and Monash University, Mary Crowley Cancer Research Center,
Abstract
ctDNA detection in patients with brain metastases arising from solid tumors.Org: Duke University Medical Center, Department of Biostatistics & Bioinformatics & CALGB Statistical Center, Duke Cancer Institute, Duke University Cancer Institute, Dana-Farber Cancer Institute,
Abstract
Phase 1/1b study of SY-5609, a selective and potent CDK7 inhibitor, in advanced solid tumors and in 2L/3L pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine +/- nab-paclitaxel.Org: Sarah Cannon Research Institute and Sidney Kimmel Cancer Center, Thomas Jefferson University, Thomas Jefferson University, START Midwest, Grand Rapids, MI, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, START San Antonio,
Abstract
Real-world outcomes with adjuvant nonsteroidal aromatase inhibitors (NSAIs) vs tamoxifen (TAM) in patients with hormone receptor−positive/human epidermal growth factor receptor 2−negative (HR+/HER2−) early breast cancer (EBC): A US database analysis.Org: Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Dana-Farber Cancer Institute, Florida Cancer Specialists and Research Institute, Ocala, FL, Memorial Sloan Kettering Cancer Center,
Abstract
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I).Org: Memorial Sloan Kettering Cancer Center, University of Wisconsin, Madison, Hoag Memorial Hospital Presbyterian, Newport Beach, CA, University of California Irvine, Sarah Cannon and HCA Research Institute,
Abstract
Alliance A022104/NRG-GI010: A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer—The Janus Rectal Cancer trial.Org: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Alliance Statistics and Data Center, Mayo Clinic, University of North Carolina at Chapel Hill,
Abstract
SPARK, studying pathways of resistance in KRAS-driven cancers: A remote plasma ctDNA participation study to identify mechanisms of resistance to KRAS inhibitors.Org: Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology, Kras Kickers, GO2 Foundation for Lung Cancer, Addario Lung Cancer Medical Institute,
Abstract
Artificial intelligence algorithm developed to predict immune checkpoint inhibitors efficacy in non–small-cell lung cancer.Org: University Hospital of North Norway, UiT The Arctic University of Norway, Brigham and Women's Hospital/Massachusetts General Hospital, Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology,
Abstract
XRay Vision: A phase 3 study of xevinapant plus radiotherapy (RT) for high-risk, cisplatin-ineligible patients with resected, locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).Org: University of Pittsburgh Medical Center, University of Birmingham, Dana-Farber Cancer Institute, National Cancer Center Hospital East, Kashiwa, Japan, UCSF Medical Center-Mount Zion,
Abstract
SARC037: Results of phase I study of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in relapsed/refractory Ewing sarcoma (ES).Org: Children's Hospital of Philadelphia, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Pediatric Oncology Branch, Clinical Center National Institutes of Health, Clinical Center National Institutes of Health, NIH / NCI,
Abstract
Circulating tumor DNA as a marker of recurrence risk in locoregional esophagogastric cancers with pathologic complete response.Org: Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Vanderbilt University Medical Center, Nashville, TN, Dana-Farber Cancer Institute, Boston, MA,
Abstract
Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.Org: Memorial Sloan Kettering Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Johannes-Gutenberg University Clinic, Clinica San Carlos de Apoquindo, Pontificia Universidad Católica, Fundacion Arturo López Pérez,
Abstract
Alliance A021804: A prospective, multi-institutional phase II trial evaluating temozolomide versus temozolomide and olaparib for advanced pheochromocytoma and paraganglioma.Org: National Cancer Institute/National Institutes of Health, Dana-Farber Cancer Institute, Alliance Statistics and Data Management Center, Mayo Clinic, Lehigh Valley Health Network,
Abstract
Biomarkers of response to first-line nivolumab therapy in patients with advanced renal cell carcinoma (RCC) enrolled in the HCRN GU16-260 trial.Org: Brigham and Women's Hospital/Massachusetts General Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, Harvard Medical School, Yale University,
Abstract
Leveraging longitudinal clinical annotations and panel sequencing to characterize dynamics of organotropism in metastatic melanoma.Org: Dana-Farber Cancer Institute, Peking University Cancer Hospital and Institute (Beijing Cancer Hospital), Beijing, China, AstraZeneca, Massachusetts General Hospital,
Abstract
Landscape and impact of germline pathogenic variants (PVs) in metastatic hormone sensitive prostate cancer (mHSPC): Ancillary study of E3805 CHAARTED.Org: Dana-Farber Cancer Institute, University College London Cancer Institute, South Australian Immunogenomics Cancer Institute,
Abstract
Uncertainty and coping in patients with newly diagnosed indolent non-Hodgkin’s lymphoma (iNHL).Org: Massachusetts General Hospital, Dana-Farber Cancer Institute,
Abstract
Towards improvement of oncology care through digital technology: A snapshot of Resilience remote patient monitoring (RPM) system implementation across 19 hospitals in Europe.Org: Resilience and Católica Medical School, Universidade Católica Portuguesa, Paris, France, Centre Hospitalier de Valenciennes, Valenciennes, France,
Abstract
Peripheral blood epigenetic immune-profiling and survival outcomes with anti-programmed death (PD)-1 based therapy in recurrent/metastatic (R/M) squamous cell carcinoma of head and neck (SCCHN).Org: Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Dartmouth Geisel School of Medicine, Brown University - Lifespan Cancer Institute, University of California San Francisco,
Abstract
Emerging phase 1 data of BLU-451 in advanced NSCLC with EGFR exon 20 insertions.Org: City of Hope- Long Beach Elm, Perlmutter Cancer Center, New York University Langone Health, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Dana-Farber Cancer Institute, Northwestern Medicine Devleopmental Therapeutics Institute,
Abstract
Comparative real-world (RW) evidence on darolutamide (Daro), enzalutamide (Enza), and apalutamide (Apa) for patients (Pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the United States: DEAR.Org: Dana-Farber Cancer Institute, Carolina Urologic Research Center, Bayer HealthCare Pharmaceuticals Inc., Bayer Consumer Care AG, Bayer PLC,
Abstract
Exercise to enhance cardiovascular health among Black patients with prostate cancer with androgen deprivation therapy: The POWER trial.Org: Dana-Farber Cancer Institute, Boston, MA, Beth Israel Deaconess Medical Center, Harvard Medical School, Harvard T. H. Chan School of Public Health,
Abstract
Phase III study of local or systemic therapy intensification directed by PET in prostate cancer patients with post-prostatectomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.Org: Abramson Cancer Center, Dana-Farber Cancer Institute, University of Wisconsin SMPH, Department of Radiology, University of Wisconsin Carbone Cancer Center, Brown University School of Public Health,
Abstract
NRG-GU012: Randomized phase II stereotactic ablative radiation therapy (SABR) for patients with metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI).Org: Medical College of Wisconsin, NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, Dana-Farber Cancer Institute, Harvard Medical School, University Hospitals Seidman Cancer Center,
Abstract
Recommendations for medical cannabis use in cancer patients by US oncology fellows and the impact of receiving prior training.Org: Beth Israel Deaconess Medical Center, University of Massachusetts Memorial Health, Tufts Medical Center/Tufts University, Dana-Farber Cancer Institute,
Abstract
ACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2–expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after 177Lu somatostatin analogue (SSA) therapy: Initial safety analysis.Org: Advanced Molecular Imaging and Therapy, Hoag Family Cancer Institute and University of Southern California, MD Anderson Cancer Center, Moffitt Cancer Center and Research Institute, Nebraska Cancer Specialists,
Abstract
Twenty-one gene recurrence scores in individuals with breast cancer associated with CHEK2 and ATM germline pathogenic variants.Org: University of Pennsylvania, Basser Center for BRCA, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Mayo Clinic,
Abstract
Clinical and molecular features of long-term response to anti-PD-(L)1 therapy in patients with advanced non-small cell lung cancer.Org: Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology, Clinical Oncology Center, Polytechnic University of Marche,
Abstract
Amplification of wild-type RET and clinical response to selpercatinib for non–small-cell lung cancer (NSCLC).Org: Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology, Brigham and Women’s Hospital, Massachusetts General Hospital, Broad Institute of MIT and Harvard,
Abstract
Ibrutinib dose modifications for management of cardiac adverse events in patients with B-cell malignancies: Pooled analysis of 10 clinical trials.Org: Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, CLL Center, Dana-Farber Cancer Institute,
Abstract
First results from the RETgistry: A global consortium for the study of resistance to RET inhibition in RET-altered solid tumors.Org: Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Lombardi Comprehensive Cancer Center, University of Berne and Cantonal Hospital of Lucerne,
Abstract
First in human phase Ⅰ study of BMS-986299 as monotherapy and combined with nivolumab and ipilimumab in advanced solid tumors.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center, UC Davis Comprehensive Cancer Center, Sacramento, CA, Dana-Farber Cancer Institute, Department of Medical Oncology, University of California San Diego,
Abstract
FDA pooled analysis of overall survival according to depth of response as a continuous variable in frontline advanced immuno-oncology renal cell carcinoma trials.Org: US Food and Drug Administration, U.S. Food and Drug Administration, FDA/CDER, Food and Drug Administration, Oncology Center of Excellence,
Abstract
Disparity in regional recruitment across global cancer trials: A meta-analysis.Org: Creighton University School of Medicine Phoenix Regional Campus, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Mayo Clinic, Fatima Jinnah Medical University, University of Arizona,
Abstract
Engagement of patient participation in genomics research by the Osteosarcoma and Leiomyosarcoma Count Me In Projects of the Cancer Moonshot funded PE-CGS Network.Org: Dana-Farber Cancer Institute, Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, Broad Institute of MIT and Harvard,
Abstract
SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Washington University School of Medicine in St Louis, Mayo Clinic, University of Washington and Fred Hutchinson Cancer Research Centre,
Abstract
Characterizing the digital divide in a diverse cohort of African American (AA) patients (pts) with prostate cancer (PCa).Org: Dana-Farber Cancer Institute, Brigham and Women's Hospital/Massachusetts General Hospital, Emory University School of Medicine, Division of Urological Surgery and the Center for Surgery and Public Health, Harvard Medical School,
Abstract
Safety, pharmacokinetics (PK), and clinical activity of bezuclastinib + sunitinib in previously-treated gastrointestinal stromal tumor (GIST): Results from part 1 of the phase 3 Peak study.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, Dana-Farber Cancer Institute, Harvard Medical School, University Hospital Essen,
Clinical trial
A Phase I/II Study of Copanlisib Plus Venetoclax for the Treatment of Relapsed/Refractory Diffuse Large B-cell LymphomaStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Phase II Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell CarcinomaStatus: Active (not recruiting), Estimated PCD: 2019-11-13
Clinical trial
A Phase 0 Pilot Study of Memory-like Natural Killer (NK) Cell Immune Therapy in Combination With N-803 in Patients With Renal Cell Carcinoma or Urothelial CarcinomaStatus: Not yet recruiting, Estimated PCD: 2025-02-28
Clinical trial
A Phase 1 Study of LY3214996, an ERK1/2 Inhibitor, in Patients With AML Who Are Not Candidates for Standard TherapyStatus: Recruiting, Estimated PCD: 2024-02-20
Abstract
Outcomes according to treatment received for small node-negative HER2+ breast tumors in the Surveillance, Epidemiology, and End Results (SEER) database, 2010-2019.Org: Dana-Farber Cancer Institute, Unidad Oncologica de Neuquen, Cooperative Oncological Group of Sur, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Identifying clinical trial candidates using AI predictions of treatment change: A pilot implementation study.Org: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center,
Abstract
A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.Org: DFCI/BWH Cancer Center, University of Chicago, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland, Rutgers Cancer Institue of New Jersey, University of Toronto,
Abstract
The role of volume of disease for treatment selection in patients with metastatic castration sensitive prostate cancer (mCSPC): A living meta-analysis.Org: Mayo Clinic, Dana-Farber Cancer Institute, Mayo Clinic Department of Digital Health, Dow Medical College, Karachi, Pakistan, Mayo Clinic Department of Pediatric and Adolescent Medicine,
Abstract
CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.Org: Memorial Sloan Kettering Cancer Center, Sarah Cannon Research Institute/Tennessee Oncology, UPMC Hillman Cancer Center, Abramson Cancer Center, Karmanos Cancer Institute,
Abstract
Determinants of resistance to nivolumab (nivo) monotherapy investigated through genomic and transcriptomic analysis of renal cell carcinoma (RCC) tumors from the HCRN GU16-260 study.Org: School of Medicine, Zhejiang University, Hangzhou, China, Yale University, New Haven, CTI BioPharma, Keck School of Medicine of the University of Southern California,
Abstract
Defining the educational needs for a community-based hematology/oncology career: A national needs assessment.Org: Mercy Catholic Medical Center, Lansdowne, PA, Darby, PA, Beth Israel Deaconess Medical Center, Boston, MA, Association of American Cancer Institutes,
Abstract
Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial.Org: Dana-Farber Cancer Institute, Kindai University Faculty of Medicine, Osaka-Sayama, Japan, Bristol Myers Squibb, Institut Curie, Saint Cloud, France, McGill University Health Center,
Abstract
Depth of radiographic response (DpR) and time to tumor regrowth (TTG) to predict overall survival following anti-VEGF therapy in recurrent glioblastoma.Org: Novartis Pharma AG, F. Hoffmann-La Roche Ltd, Exelixis, Inc., VBL Therapeutics, Dana-Farber Cancer Institute,
Abstract
Clonal hematopoiesis in the phase 3 Alliance A031201 trial of metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor (AR)-targeted therapies.Org: Mayo Clinic, Mayo Clinic Alliance Statistics and Data Center, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, UCI Health,
Abstract
Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.Org: Levine Cancer Institute, Wilmot Cancer Institute, BC Cancer Centre for Lymphoid Cancer, Willamette Valley Cancer Institute and Research Center, US Oncology Research,
Abstract
A phase II study of nivolumab and ipilimumab with radiation therapy in patients with metastatic, microsatellite stable colorectal cancer.Org: Harvard Radiation Oncology Program, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School,
Abstract
Should I stay, or should I go? Factors associated with intent to leave academic oncology.Org: University of California San Francisco, University of Utah, Dana-Farber Cancer Institute, Harvard Medical School, Memorial Sloan Kettering Cancer Center,
Abstract
Neoplasia detection via colonoscopic surveillance among young patients with MSH6 and PMS2-associated Lynch syndrome.Org: Memorial Sloan Kettering Cancer Center, University of Pennsylvania, Dana-Farber Cancer Institute, University of Pennsylvania Perelman School of Medicine,
Abstract
Prevalence of unexpected actionable germline pathogenic variants identified on broad-based multi-gene panel testing in a cohort of cancer patients.Org: University of Vermont Larner College of Medicine, Dana-Farber Cancer Institute,
Abstract
Novel curriculum for training in medical cannabis in oncologic populations for oncology trainees.Org: Beth Israel Deaconess Medical Center, University of Massachusetts Memorial Health, Loma Linda University Department of Radiation Technology, Dana-Farber Cancer Institute, Tufts Medical Center/Tufts University,
Abstract
Clinical evaluation of cancer signal origin prediction and diagnostic resolution following multi-cancer early detection testing.Org: GRAIL, LLC, a subsidiary of Illumina, Inc., Illumina, Inc., Sutter Health, Intermountain Healthcare, Mayo Clinic,
Abstract
Association of remote, longitudinal patient-reported outcomes (PROs) and step counts with hospitalization or death among patients with advanced cancer undergoing chemotherapy: Secondary analysis of the PROStep randomized trial.Org: Perelman School of Medicine, University of Pennsylvania, Hospital of the University of Pennsylvania, Penn Medicine at Lancaster General Health, Ascension Health,
Abstract
Endocrine therapy resistance (ETR) in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+, HER2– mBC): Prevalence, biomarker characteristics, and outcomes.Org: Dana-Farber Cancer Institute, Genentech, F. Hoffmann-La Roche Ltd, University Hospitals Seidman Cancer Center, Massachusetts General Hospital,
Abstract
Disease outcomes by race in patients with high-risk triple negative breast cancer with residual disease after neoadjuvant chemotherapy: A post-hoc analysis of the EA1131 randomized clinical trial.Org: Brigham and Women's Hospital/Massachusetts General Hospital, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Dana-Farber Cancer Institute, MD Anderson Cancer Center, Division of Breast Surgery,
Abstract
Association of pretreatment chest CT abnormalities with trastuzumab deruxtecan–associated pneumonitis.Org: Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, Dana-Farber Cancer Institute,
Abstract
Impact of vitamin d on the colon tumor immune microenvironment: Results of a randomized clinical trial of preoperative vitamin D supplementation in patients with stage I-III colon cancer.Org: Dana-Farber Cancer Institute, Brigham and Women's Hospital/Massachusetts General Hospital, DFCI/PCC Fellowship Program - Attendings, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Dana-Farber/Partners CancerCare,
Abstract
A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects.Org: National Cancer Institute, Vilnius, Lithuania, NYU Langone Laura and Isaac Perlmutter Cancer Center, Dana-Farber Cancer Institute, University of California Davis, Sacramento, CA, University of Colorado Cancer Center Anschutz Medical Campus,
Abstract
KRAS G12C-mutated pancreatic cancer: Clinical outcomes based on chemotherapeutic regimen.Org: Caris Life Sciences, Irving, TX, Hoag Memor Hosp, Barbara Ann Karmanos Cancer Institute, Dana-Farber Cancer Institute, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ,
Abstract
Impact of immune checkpoint inhibition on ovarian reserve in patients with melanoma enrolled in the ECOG-ACRIN E1609 adjuvant trial.Org: Dana-Farber Cancer Institute, Boston, MA, Brigham and Women's Hospital/Massachusetts General Hospital, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL,
Abstract
Deep learning to estimate RECIST in cancer patients treated in real-world settings.Org: Dana-Farber Cancer Institute, Harvard Medical School, Massachusetts General Hospital,
Abstract
XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers.Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Summit Cancer Centers, Spokane Valley, WA, Virginia Cancer Specialists, Perlmutter Cancer Center at NYU Langone Health Medical Center,
Abstract
A phase 2 study of the WEE1 inhibitor AZD1775 in SETD2-deficient advanced solid tumor malignancies.Org: University of California San Francisco, Vanderbilt University Medical Center, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Robert H. Lurie Comprehensive Cancer Center of Northwestern University,
Abstract
Are enrollment criteria for phase II and III clinical trials in acute myeloid leukemia arbitrarily restrictive?Org: Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, Dana-Farber Cancer Institute,
Abstract
SGN-B6A, an integrin beta-6 (ITGB6)-targeted antibody-drug conjugate (ADC), in patients with advanced solid tumors: Updated results from a phase 1 study (SGNB6A-001).Org: Institut Gustave Roussy, The Royal Marsden Hospital (Surrey), London, United Kingdom, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University Hospitals Seidman Cancer Center, START San Antonio,
Abstract
Characterization of the immunophenotype and tumor specificity of CD8+ T-cells in chromophobe renal cell carcinoma (ChRCC) and renal oncocytic neoplasms.Org: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, St. Elizabeth's Medical Center, Brighton, MA,
Abstract
Phase 1 results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) or gemcitabine (gem) in advanced solid tumors.Org: University of Washington/Fred Hutchinson Cancer Research Center, University of California, San Francisco, Division of Endocrinology, San Francisco, CA, Sarah Cannon Research Institute at HealthONE, University of Michigan Rogel Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Initial chemotherapy for locally advanced and metastatic NUT carcinoma: A report from the NUT Carcinoma Registry.Org: Dana-Farber Cancer Institute, Boston, MA, Brigham and Women's Hospital/Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
Novel use of alternate (Alt) response (Rp) criteria (Cr) for early prediction of outcomes in pancreatic (P) neuroendocrine tumors (NETs): Utilizing banked imaging data from the ECOG-ACRIN E2211 study.Org: Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, Yale Cancer Center, Yale School of Medicine, New Haven, CT, New Haven, CT,
Abstract
Phase 3 TRIDENT study (EF-32): Tumor treating fields (TTFields; 200 kHz) concomitant with chemoradiation, and maintenance TTFields therapy/temozolomide in newly diagnosed glioblastoma.Org: Novocure Inc., Thomas Jefferson University, University of Montreal, Johns Hopkins University School of Medicine, Tufts Medical Center/Tufts University,
Abstract
Survival outcomes with CPX-351 vs 7+3 by baseline bone marrow blast percentage in older adults with newly diagnosed high-risk or secondary acute myeloid leukemia: A 5-year follow-up study.Org: Jazz Pharmaceuticals, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Dana-Farber Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, H. Lee Moffitt Cancer Center and Research Institute,
Abstract
The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.Org: Mount Sinai Health System, SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Dana-Farber Cancer Institute, SWOG Statistical Center,
Abstract
Efficacy and safety of sunvozertinib in treatment naïve NSCLC patients with EGFR exon20 insertion mutations.Org: Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China, National Taiwan University Hospital Yunlin Branch, National Taiwan University Cancer Center/Hospital, Taipei Veterans General Hospital, Chang Gung Memorial Hospital at Linkou and Chang Gung University,
Abstract
Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.Org: Samsung Medical Center, Vall d’Hebron University Hospital/VHIO, Memorial Sloan Kettering Cancer Center, Tennessee Oncology, PLLC, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh).Org: Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, Department of Data Sciences, Winship Cancer Institute of Emory University,
Abstract
Clinical genomic implications of transcriptional subtypes in pancreatic cancer.Org: Dana-Farber Cancer Institute, Brookline, MA, Boston, MA, Caris Life Sciences, Irving, TX, Phoenix, AZ,
Abstract
Multi-omic characterization of gastrointestinal stromal tumor (GIST) in a large real-world patient cohort.Org: Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Miller School of Medicine, Miami, FL, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Caris Life Sciences, Irving, TX, Lombardi Comprehensive Cancer Center,
Abstract
Machine learning (ML)-based quantification of tumor-infiltrating lymphocytes (TIL) and clinical outcomes of patients with melanoma treated with immune-checkpoint inhibitors (ICI).Org: Brigham and Women's Hospital/Massachusetts General Hospital, University Hospital of North Norway, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Dana-Farber Cancer Institute,
Abstract
RANO 2.0: Proposal for an update to the Response Assessment in Neuro-Oncology (RANO) Criteria for high- and low-grade gliomas in adults.Org: Dana-Farber Cancer Institute, Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands, Ronald Reagan UCLA Medical Center, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, Stanford University, Stanford, CA, California Pacific Medical Center Research Institute, San Francisco, CA, Women's Health Integrated Research Center at Inova Health System, Annandale, VA, Women’s Health Integrated Research Center at Inova Health System, Department of Defense Gynecologic Cancer Center of Excellence, Annandale, VA, Stanford University Medical Center, Palo Alto, CA, Pingtung Veterans General Hospital, Pingtung, South Korea, University Hospital and University of Zurich,
Abstract
Plasma cell leukemia: A multicenter retrospective study of 150 patients.Org: The University of Arizona Cancer Center, University of Arizona Cancer Center, The University of Utah Huntsman Cancer Institute, Salt Lake City, UT, Department of Internal Medicine, University of Utah, Fred Hutchinson Cancer Research Center,
Abstract
Updated results from a phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor rivoceranib for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul National University Hospital, University of Colorado Health Science Center, University of California Los Angeles,
Abstract
Immune landscape of patients with metastatic non-clear cell renal cell carcinoma (nccRCC) treated with atezolizumab plus bevacizumab.Org: Dana-Farber Cancer Institute, Dana-Farber Cancer Institute and Harvard Medical School, Brigham and Women's Hospital/Massachusetts General Hospital, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, Department of Medical Oncology, Gustave Roussy,
Abstract
evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC).Org: Dana-Farber Cancer Institute, UPMC Hillman Cancer Center, University of Pittsburgh Cancer Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Memorial Sloan Kettering Cancer Center,
Abstract
Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58.Org: SOLTI Cancer Research Group, Ohio State University Comprehensive Cancer Center, Novartis Pharmaceuticals, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, University of North Carolina School of Medicine,
Abstract
Characterizing telomerase reverse transcriptase (TERT) promoter mutations (mut) across sex, race, and cancer types.Org: Dana-Farber Cancer Institute, Harvard Medical School, Lebanese University, Faculty of Medical Sciences, Department of Data Sciences,
Abstract
Trop-2 mRNA expression and association with clinical outcomes with sacituzumab govitecan (SG) in patients with HR+/HER2– metastatic breast cancer (mBC): Biomarker results from the phase 3 TROPiCS-02 study.Org: Medical Oncology Group, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Harvard Medical School, Boston, MA, Department of Medicine, Icahn School of Medicine at Mount Sinai,
Abstract
EO2401 (E) peptide immunotherapy + nivolumab (N) +/- bevacizumab (B) in recurrent glioblastoma (GB): EOGBM1-18/ROSALIE.Org: Universitätsklinikum Heidelberg, German Cancer Research Center, Sorbonne Université, AP-HP at Saint-Louis Hospital, ICM,
Abstract
HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS.Org: Duke University Medical Center, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Grande Ospedale Metropolitano Niguarda and Università degli Studi di Milano,
Abstract
Reporting and impact of subsequent cycle toxicities in oncology phase I clinical trials.Org: Harvard Medical School, Dana-Farber Cancer Institute, Children’s Mercy Hospitals and Clinics,
Abstract
Impact of smoking status (SS) on the clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first line (1L) immuno-oncology (IO)-combination regimens: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).Org: Huntsman Cancer Institute at the University of Utah, Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Harvard Medical School, BC Cancer Agency Vancouver Island Centre, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada,
Abstract
Long-term survival with IDH wildtype glioblastoma: First results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419).Org: University Hospital and University of Zurich, Institute of Neuropathology, University Hospital Düsseldorf, University of California, San Francisco, Division of Endocrinology, San Francisco, CA, University and City of Health and Science Hospital,
Abstract
Anti-tumor activity of sunvozertinib in NSCLC with EGFR sensitizing mutations after failure of EGFR TKI treatment.Org: Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijng, China, Chi Mei Chest Hospital, Department of Oncology, National Cheng Kung University Hospital, Blacktown Hospital, St. George Hospital,
Abstract
Sexual dysfunction in women with lung cancer: Updates from the SHAWL study.Org: Dana-Farber Cancer Institute, Harvard Medical School, University of California San Francisco, Brigham and Women's Hospital/Massachusetts General Hospital, Rush University Medical Center,
Abstract
A multi-center natural history study of precision-based genomics in prostate cancer (PC).Org: Dana-Farber Cancer Institute, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, Memorial Sloan Kettering Cancer Center, University of California San Diego,
Abstract
Prognostic significance of pretreatment immune cell infiltration in muscle invasive bladder cancer treated with definitive chemoradiation: Analysis of NRG RTOG 0524 and 0712.Org: University of Maryland Capital Region, Massachusetts General Hospital, Helen Diller Family Comprehensive Cancer Center, University of California Irvine, Dana-Farber Cancer Institute,
Abstract
Association of host immune signatures with response to immunotherapy-based regimens in patients with metastatic renal cell carcinoma (mRCC).Org: Dana-Farber Cancer Institute, Harvard Medical School, Dartmouth College Geisel School of Medicine, Brigham and Women's Hospital/Massachusetts General Hospital, School of Medicine, Yale University, New Haven, CT,
Abstract
Apollo: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2, or PALB2 mutation—ECOG-ACRIN EA2192.Org: University of Pennsylvania, Dana-Farber Cancer Institute, University of Kansas Cancer Center, Kansas City, KS, Memorial Sloan Kettering Cancer Center, Winship Cancer Center of Emory University,
Abstract
Post radical prostatectomy (RP) PSA outcomes following 6 vs 18 months of perioperative androgen deprivation therapy (ADT) in men with localized high risk prostate cancer (LHRPC): Results of Part 2 of a randomized phase 2 trial.Org: Dana-Farber Cancer Institute, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, Beth Israel Deaconess Medical Center, Janssen Research & Development,
Abstract
Depth of PSA nadir and subsequent PSA progression-free survival in patients (pts) with high-risk biochemically relapsed prostate cancer: Results from the phase 3 PRESTO study (AFT-19).Org: Alliance Statistics and Data Management Center, Mayo Clinic, Mayo Clinic Alliance Statistics and Data Center, Memorial Sloan Kettering Cancer Center at Basking Ridge New Jersey, Dana-Farber Cancer Institute,
Abstract
Association of neutrophil to eosinophil ratio (NER) with clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with first-line (1L) immune checkpoint inhibitors (ICI) –based regimens.Org: Dana-Farber Cancer Institute, Harvard Medical School,
Abstract
Safety and efficacy of immune checkpoint inhibitors (ICIs) in patients (pts) with cardiac metastases (mets) from solid tumors.Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Dana-Farber Cancer Institute and Harvard Medical School, University of Texas MD Anderson Cancer Center,
Abstract
Phase II study of crizotinib in patients with MET amplification and MET exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2.Org: St. James’s Hospital, Dana-Farber Cancer Institute, University of Texas MD Anderson Cancer Center, Jefferson Kimmel Cancer Center at Jefferson Health, NCI,
Abstract
Clinical efficacy of avapritinib in gastrointestinal stromal tumors (GIST) with different KIT genotypes: Post hoc analysis of the phase 1 NAVIGATOR and phase 1/2 CS3007-101 trials.Org: Portland VA Health Care System, OHSU Knight Cancer Institute, Portland, OR, Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, The First Affiliated Hospital of Sun Yat-sen University,
Abstract
A multi-institutional prospective cohort study of minimal residual disease in peripheral T-cell lymphoma: Impact of autologous stem cell transplant.Org: Washington University School of Medicine in St Louis, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Invivoscribe, Inc.,
Abstract
Biomarkers of response to sacituzumab govitecan (SG) and efficacy after treatment with enfortumab vedotin (EV) in advanced urothelial carcinoma (aUC): Analysis of the UNITE study.Org: University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, MD Anderson Hematology/Oncology Fellowship, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Washington and Fred Hutchinson Cancer Research Centre,
Abstract
EXCALIBER-RRMM: A phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).Org: Winship Cancer Center of Emory University, St. Vincent’s Hospital, University of Melbourne, National and Kapodistrian University of Athens, Clínica Universidad de Navarra and CIBEREHD,
Abstract
Tumor-intrinsic features associated with progression-free survival (PFS) in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel).Org: Bristol Myers Squibb, Mount Sinai Medical Center, Dana-Farber Cancer Institute,
Abstract
Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).Org: Duke University Medical Center, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, MRC Clinical Trials Unit at UCL, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, SWOG Statistical Center,
Abstract
Clinical, pathologic, and genomic hallmarks of KRAS-amplified non-small cell lung cancer.Org: Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology, Harvard University, Clinical Oncology Center, Polytechnic University of Marche,
Abstract
Financial toxicity and quality of life in patients undergoing bone marrow transplant evaluation: A single center analysis.Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Hospital, Duke Cancer Institute Biostatistics, Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Duke Cancer Institute, Levine Cancer Inst/Carolinas Medcl Ctr,
Abstract
A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.Org: Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, Department of Data Sciences, Dana-Farber Cancer Institute,
Abstract
Disparities in uptake of novel therapies for acute myeloid leukemia.Org: Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, Dana-Farber Cancer Institute,
Abstract
Rates of emergency department visits and acute-care hospital admissions after starting chemotherapy or having surgery across six community-based cancer centers.Org: Dana-Farber Cancer Institute, Dartmouth-Hitchcock Medical Center, MaineHealth Cancer Care, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, WVU Cancer Institute,
Abstract
Phase 1 dose-expansion study of oral TP-1287, a cyclin-dependent kinase 9 (CDK9) inhibitor, in patients with Ewing sarcoma (EWS).Org: MGH Cancer Center, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Medical College of Wisconsin, Norris Comprehensive Cancer Center,
Abstract
Prognosis and trends in chemotherapy use for patients with stage IA triple-negative breast cancer (TNBC): A population-based study.Org: Dana-Farber Cancer Institute, Cooperative Oncological Group of Sur, Unidad Oncologica de Neuquen, Department of Medical Oncology, Dana-Farber Cancer Institute,
Abstract
PEPN1924, a phase 2 study of trastuzumab deruxtecan (DS-8201a, T-DXd) in adolescents and young adults with recurrent HER2+ osteosarcoma: A Children’s Oncology Group Pediatric Early-Phase Clinical Trial Network study.Org: H. Lee Moffitt Cancer Center and Research Institute, Dana-Farber Cancer Institute, Institute for Clinical and Translational Research, Baylor College of Medicine, Baylor College of Medicine, Children's Oncology Group,
Abstract
Using telehealth to conduct serious illness conversations (SIC) for patients with metastatic lung cancer during the COVID-19 pandemic.Org: Massachusetts General Hospital, Harvard University, University of California Irvine, Dana-Farber Cancer Institute, University of Oklahoma Stephenson Cancer Center,
Abstract
Time to initial review by oncology clinical pathways committees for new FDA approvals/label expansions.Org: Dana-Farber Cancer Institute,
Abstract
Facilitating the transition to posttreatment survivorship for adolescent and young adults: A randomized waitlist control trial of a virtual mind-body intervention.Org: Massachusetts General Hospital, Dana-Farber Cancer Institute,
Abstract
Self-reported overall wellbeing and physical function among chemotherapy and surgery patients completing symptom questionnaires across six health systems.Org: Dana-Farber Cancer Institute, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Dartmouth-Hitchcock Medical Center, MaineHealth Cancer Care, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI,
Abstract
A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial).Org: Institut Gustave Roussy, Villejuif, France, Hospital Universitario 12 de Octubre, Madrid, Spain, Spain,
Abstract
Characterizing imposter syndrome among oncologists on social media.Org: Valley Health System, Paramus, NJ, Medical College of Wisconsin, Milwaukee, WI, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI,
Abstract
FDA analysis of treatment-free survival in frontline advanced immuno-oncology–VEGF TKI renal cell carcinoma trials.Org: BeiGene, COTA Healthcare Inc., NRB 501E, Department of Medicine, Vanderbilt University Medical Center, Beth Israel Deaconess Medical Center,
Abstract
The impact of large oncology meetings (#ASCO, #AACR, #ASH) and health equity hashtags (#DEI+) on social media engagement.Org: Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, Rhode Island Hospital, Dana-Farber Cancer Institute, Harvard Medical School, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Plasma KIM-1 for preoperative prediction of renal cell carcinoma versus benign renal masses, and association with clinical outcomes.Org: Dana-Farber Cancer Institute, N.N. Blokhin National Medical Research Centre of Oncology, International Agency for Research on Cancer, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital/Massachusetts General Hospital,
Abstract
INSIGHT: A phase 3, randomized, multicenter, open-label study of ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib harboring KIT exon 11 + 17 and/or 18 mutations.Org: Dana-Farber Cancer Institute, Centre Léon Bérard, Memorial Sloan Kettering Cancer Center, Sarcoma Unit, Vall d’Hebron Institute of Oncology (VHIO),
Abstract
Evaluation of local control strategies on patterns of treatment failure in patients with localized Ewing sarcoma treated on AEWS1031: A report from the Children’s Oncology Group.Org: Mayo Clinic Arizona, Phoenix, AZ, Moffitt Cancer Center, Children's Oncology Group, Public Health Institute, United Arab Emirates University, Alain, United Arab Emirates, Department of Radiation Oncology, University of Florida College of Medicine Jacksonville,
Abstract
Multi-modal and longitudinal characterization of the tumor and immune microenvironment from primary to in-transit and distant metastasis in acral melanoma.Org: Dana-Farber Cancer Institute, Universitatsklinikum Essen Klinik fur Dermatologie, Laboratory of Systems Pharmacology, Harvard Medical School, Department of Applied Computational Cancer Research,
Abstract
Comprehensive Outcomes for After Cancer Health: COACH.Org: University of Nebraska Medical Center, Nebraska Medicine Bellevue, University of Nebraska Medical Center College of Nursing, The Ohio State University - James Cancer Hospital, Pack Health, A Quest Diagnostics Company,
Abstract
Novel blood-based assay for detection of early stage multi-cancer.Org: University of California, Davis, Sacramento, CA, Dana-Farber Cancer Institute, Boston, MA, Harbinger Health,
Abstract
Key difference-making conditions distinguishing ASCO members’ institutions that collect sexual orientation and gender identity (SOGI) data from those that do not.Org: GW Cancer Center, University of Texas Southwestern Medical Center, Regenstrief Institute, American Society of Clinical Oncology, MD Anderson Cancer Center,
Abstract
Cryptococcosis in non-HIV/non-transplant hematological patients: A 12-year retrospective clinical analysis in a Peruvian referral cancer center.Org: Dana-Farber Cancer Institute, Instituto Nacional de Enfermedades Neoplasicas, Lima, 51, Peru, Universidad Nacional Mayor de San Marcos, Hospital das Clinicas UFMG,
Abstract
Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.Org: Texas Children's Cancer and Hematology Center, Baylor College of Medicine, Houston, TX, Dana-Farber Cancer Institute, Boston, MA,
Abstract
Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor (PARP) in patients with newly diagnosed ovarian cancer: A systematic review and meta-analysis.Org: Centro de Oncologia do Parana, Princess Margaret Hospital, Catholic University of Pelotas, Universidade de Brasília, UNICENTRO,
Abstract
Real-world evidence study of treatment patterns and outcomes following covalent BTKi discontinuation in a contemporary cohort of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients.Org: Dana-Farber Cancer Institute, Boston Pharmaceuticals, MaaT Pharma, Analysis Group, Inc., Inc.,
Abstract
Initial results from the phase (ph) 1 portion of a ph 1/2 study of THE-630 in patients (pts) with advanced gastrointestinal stromal tumor (GIST).Org: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Fox Chase Cancer Center, HonorHealth Research Institute, University of Miami Sylvester Comprehensive Cancer Center,
Abstract
A supervised remote exercising program for patients receiving immunotherapy alone or in combination with chemotherapy in Brazil: ExIO.Org: Centro de Cancer de Brasilia, Instituto Unity de Ensino e Pesquisa, Grupo Oncoclinicas, Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Rio De Janeiro, Brazil, Hospital Universitario de Brasilia,
Abstract
Pilot randomized trial of a telehealth intervention for women with advanced ovarian cancer and PARP inhibitor-related fatigue.Org: Dana-Farber Cancer Institute, University of Colorado Anschutz Medical Campus, Harvard Medical School, University of Colorado Boulder, University of Pennsylvania,
Abstract
External validation of biomechanical computed tomography for fracture risk classification in metastatic hormone sensitive prostate cancer.Org: MD Anderson Cancer Center, University of Pennsylvania School of Medicine, University of Pennsylvania, O.N. Diagnostics, University of California, Berkeley,
Clinical trial
Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast CancerStatus: Not yet recruiting, Estimated PCD: 2026-09-01
Clinical trial
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)Status: Active (not recruiting), Estimated PCD: 2019-08-26
Abstract
Effect of the COVID-19 pandemic on radical prostatectomy: A Brazilian retrospective study.Org: Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, Federal University of Piaui, Teresina, Brazil, Dana-Farber Cancer Institute,
Abstract
ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Dana-Farber Cancer Institute, MD Anderson Cancer Center, University of Lille,
Abstract
Evaluation of bleeding risk between apixaban and rivaroxaban in patients with gastrointestinal cancer.Org: Emory University Hospital Midtown, Winship Cancer Institute of Emory University, Dana-Farber Cancer Institute, Astellas Pharma, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA,
Abstract
Trends in utilization of first-line palliative care in non-metastatic hepatocellular carcinoma.Org: Dana-Farber Cancer Institute, University of Texas Southwestern Medical Center, University of Florida/UF Health Cancer Center,
Abstract
ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68).Org: College of Medicine, University of Cincinnati, Wexner Medical Center and The James Cancer Hospital, Ohio State University, Women's Cancer Care Associates, Arizona Oncology Associates, Texas Oncology - Fort Worth Cancer Center,
Abstract
Evaluating the impact of exercise in women living with indolent metastatic breast cancer: The EMBody trial.Org: IU School of Medicine, IUPUI School of Health and Human Sciences, Indiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, METAvivor, Project Life,
Abstract
BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.Org: Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, Faculty Hospital Hradec Kralove,
Abstract
Nominating molecular/immunologic drivers of central nervous system (CNS) metastases in squamous cell carcinoma of the head/neck (SCCHN).Org: Pritzker School of Medicine, The University of Chicago Medicine Center for Advanced Care at Orland Park, MD Anderson Hematology/Oncology Fellowship, Canter for Head and Neck Oncology, Dana-Farber Cancer Institute,
Abstract
From the lab to the clinic: Lessons learned from a translational working group.Org: Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Division of Surgical Oncology, Department of Surgery, The Ohio State University, Durham, NC, COMET Study Patient Leadership Team, San Francisco, CA,
Abstract
A phase 1 study to assess BDTX-1535, an oral EGFR inhibitor, in patients with glioblastoma or non–small-cell lung cancer.Org: Lung Cancer Research, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Sarah Cannon Research Institute at HealthONE, Next Oncology Virginia and Virginia Cancer Specialists,
Abstract
Adjuvant endocrine therapy adherence changes among patients after a virtual behavioral intervention.Org: Massachusetts General Hospital, University of Miami Miller School of Medicine, Miami, FL, Dana-Farber Cancer Institute,
Abstract
Mortality and the burden of subsequent malignant neoplasms in survivors of childhood cancer beyond age 50: A report from the Childhood Cancer Survivor Study (CCSS).Org: City of Hope National Medical Center, University of Alberta, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, U T MD Anderson Cancer Center, Dana-Farber Cancer Institute,
Abstract
What is your preferred language? Evaluating equal access to oncology clinical studies for non-English-speaking participants.Org: Dana-Farber Cancer Institute, Massachusetts General Hospital, Brigham and Women's Hospital/Massachusetts General Hospital, Dartmouth-Hitchcock Cancer Center, Stanford University School of Medicine,
Abstract
Subsequent meningiomas in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).Org: Dana-Farber/Boston Children's Cancer and Blood Disorders Center, University of Alberta, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Fred Hutchinson Cancer Research Center, MD Anderson Cancer Center,
Abstract
A Lasso Cox score consisting of CTLA4+ regulatory T cells (Treg), monocytic myeloid derived suppressor cells (M-MDSC), and CXCR3+ CD8+ T cells: Association with adjuvant ipilimumab (ipi) survival outcomes in patients (pts) with high-risk melanoma.Org: H. Lee Moffitt Cancer Center and Research Institute, Dana-Farber Cancer Institute, Moffitt Cancer Center, National Cancer Institute/National Institutes of Health, University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center,
Abstract
Use of statistical process control charts to identify impactful implementation strategies for an ePRO-based symptom management program across the SIMPRO Consortium.Org: Dana-Farber Cancer Institute, Lifespan Cancer Institute, The Warren Alpert Medical School of Brown University, Providence, RI, WVU Cancer Institute, MaineHealth Cancer Care, Dartmouth-Hitchcock Medical Center,
Abstract
Association of KMT2C loss-of-function mutations in circulating tumor DNA and prolonged response to the combination of PARPi and PI3Ki.Org: Mayo Clinic, Beth Israel Deaconess Medical Center, Harvard Medical School, Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute,
Abstract
Clinical and molecular characterization of HER2-low metastatic colorectal cancer.Org: Hadassah-Hebrew University Medical Center, Dana-Farber Cancer Institute,
Abstract
A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM).Org: UPMC Hillman Cancer Center, University of Oklahoma Stephenson Cancer Center, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Sidney Kimmel Cancer Center at Thomas Jefferson University,
Abstract
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).Org: University Hospital Essen, University Duisburg-Essen, West German Cancer Centre (WTZ), German Cancer Consortium (DKTK), Partner Site Munich, Partner Site Essen,
Abstract
The 2022 NCI Community Oncology Research Program (NCORP) Landscape Committee Assessment: Methods and participating practice group characteristics.Org: Wake Forest University School of Medicine, University of Alabama at Birmingham Department of Hematology, Birmingham, AL, University of Wisconsin School of Medicine and Public Health, Tufts Medical Center/Tufts University, Spartanburg Regional Healthcare System,
Abstract
Real-world clinical outcomes in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US).Org: Dana-Farber Cancer Institute, University Hospitals Leuven, Leuven, Belgium, Stanford University School of Medicine, Gilead Sciences Europe Ltd., Gilead Sciences Inc.,
Abstract
Phase 2 study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (P) in advanced gastric or gastroesophageal junction (GEJ) cancer.Org: Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Medicine, Section of Hematology & Oncology, University of Chicago Medical Center, Dana-Farber Cancer Institute, Department of Internal Medicine, Seoul National University Bundang Hospital,
Abstract
NOTOS: A pivotal study of navtemadlin, a first-in-class mouse double minute 2 inhibitor (MDM2i), in patients (pts) with TP53 wild-type (TP53WT) Merkel cell carcinoma (MCC) for whom anti PD-1/L1 therapy has failed.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Pittsburgh Medical Center, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Rogel Cancer Center, University of Michigan, Aix-Marseille University CHU Timone,
Abstract
Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in CheckMate 067.Org: Dana-Farber Cancer Institute, Veneto Institute of Oncology IOV–IRCCS, University of Colorado Cancer Center, Aix-Marseille University CHU Timone, Maria Skłodowska-Curie National Institute of Oncology Center,
Abstract
Genomic characterization of locally recurrent prostate cancer after radiation therapy.Org: Dana-Farber Cancer Institute, Ohio State University Comprehensive Canvcer Hospital, Brigham and Women's Hospital/Massachusetts General Hospital,
Abstract
RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).Org: Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, DC, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, Lecanto, FL,
Abstract
A dual institution real-world study of avelumab for advanced Merkel cell carcinoma.Org: Massachusetts General Hospital, Massachusetts Eye and Ear, Dana-Farber Cancer Institute, Harvard Medical School, Brigham and Women's Hospital/Massachusetts General Hospital,
Abstract
AI-based pathologic biomarker for pathologic downstaging in patients with muscle-invasive bladder cancer undergoing cystectomy after neoadjuvant nivolumab, gemcitabine, and cisplatin: BLAAST-1 Trial.Org: Valar Labs, Inc., Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Huntsman Cancer Institute, Hunstman Cancer Institute at the University of Utah,
Abstract
Falls and hospitalization during chemotherapy in older women with early breast cancer.Org: City of Hope National Medical Center, Duarte, CA, University of Nebraska Medical Center, Omaha NE, Neurocentria,
Abstract
Evidence-based cost estimation of essential medicines for pediatric cancer care in Peru.Org: Dana-Farber Cancer Institute, Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada, ICES, Toronto, ON, Canada, Institute for Clinical Evaluative Science, Toronto, ON, Canada, Sunnybrook Health Sciences Centre, Toronto, ON, Canada, The Hospital for Sick Children, Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru, Pan American Health Organization,
Abstract
Impact of the Covid-19 pandemic on the treatment of resectable liver neoplasms: A cross-sectional study from Brazil.Org: Faculdade de Medicina da Universidade de São Paulo, Federal University of Piaui, Dana-Farber Cancer Institute, Harvard Medical School, Universidade de Santa Cruz do Sul,
Abstract
Evaluating embedded geriatric care in gastrointestinal (GI) oncology program for older adults (OA): Feasibility and key learnings.Org: Dana-Farber Cancer Institute, Brigham and Women's Hospital/Massachusetts General Hospital, Massachusetts General Hospital,
Abstract
Investigating the patterns of treatment failure in patients with advanced stage III and IV melanoma receiving adjuvant therapy.Org: Massachusetts General Hospital, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Surgical Oncology, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Massachusetts General Hospital/Harvard Medical School, Dana-Farber Cancer Institute,
Abstract
Treatment with lenvatinib plus pembrolizumab in recurrent or advanced endometrial cancer: A systematic review and meta-analysis.Org: Federal University of Pará - UFPA, Belem, Brazil, Princess Margaret Hospital, Toronto Allergy and Asthma Centre,
Abstract
A pilot study of liposomal irinotecan plus 5-FU/LV combined with paricalcitol in patients with advanced pancreatic cancer whose disease progressed on gemcitabine-based therapy.Org: Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, Washington University School of Medicine in St Louis, St. Louis, MO, Washington University School of Medicine in St. Louis, Dartmouth Hitchcock Medical Center,
Abstract
Development of a multiphase patient-reported outcomes dashboard to support population health and drive quality improvement in ambulatory oncology.Org: Dana-Farber Cancer Institute, Informatics and Analytics, Dana-Farber Cancer Institute, Boston, MA,
Clinical trial
A Pilot Study of Pembrolizumab in Combination With Chemotherapy in Newly Diagnosed Primary Central Nervous System LymphomaStatus: Not yet recruiting, Estimated PCD: 2025-06-30